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ABSTRACT 
Globally, the status of chronic infection with hepatitis B virus (HBV) is increasing, with 
approximately twenty million new cases being reported each year. Chronically infected 
individuals are at risk of developing complications of cirrhosis and hepatocellular 
carcinomas. Currently, treatment of HBV entails a combination of therapeutics and 
successful treatment is limited to approximately 20% of patients. Efficient inhibition of HBV 
replication has been shown by harnessing the RNA interference (RNAi) pathway through 
the utilisation of U6 RNA Polymerase III (Pol III) promoter-driven short hairpin RNA 
(shRNA). The generation of a double stranded RNA (dsRNA) as a therapeutic tool is a 
realistic approach to treating HBV, however the expression of the dsRNA requires 
optimisation to prevent any toxic effects associated with off-targeting or saturation of the 
endogenous RNAi pathway. Two Pol III (H1 and tRNALys3) promoter-driven shRNA 
expression cassettes and an Pol II (CMV) promoter-driven microRNA shuttle were 
generated and compared to the U6 shRNA constructs. Knockdown was assessed for five 
different target sites at varying concentrations of effecter to target ratios. The tRNALys3 
shRNA 5 caused significant inhibition of HBV, whilst the H1 and cytomegalovirus (CMV) 
promoter-driven effecter cassettes were only effective at high target to effecter ratios 
(1:10). In vivo analysis in a murine hydrodynamic injection model supported the data from 
cell culture analysis, and established U6 shRNA 5 and tRNALys3 shRNA 5 as the most 
effective promoter-driven cassettes with which to silence HBV replication. Harnessing of 
the endogenous RNAi pathway to control the expression of HBV genes by target specific 
mRNA degradation is becoming an increasingly valuable approach in designing a 
therapeutic antiviral construct, particularly with a construct as effective as tRNALys3 shRNA 
5. 
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1 INTRODUCTION 
1.1 Hepatitis B virus  
Globally, chronic infection with the hepatitis B virus (HBV) is estimated to affect 400 million 
people, with between 10 and 20 million new infections occurring every year. HBV-related 
complications, including hepatocellular carcinoma (HCC) and cirrhosis, are responsible for 
an annual mortality rate of approximately one million individuals (26, 47, 56). Currently, 
there are three classes of therapeutic agents available to treat HBV, which comprise 
immunomodulators, nucleotide and nucleoside analogues. The existing treatment of 
chronically infected individuals entails a combinatorial approach. Therapeutics 
administered are an immunomodulator (interferon-α) with either and a nucleotide analogue 
(adefovir) or a nucleoside analogue (lamuvidine). However the success of the combination 
therapy is limited to approximately 20% of patients and the response is rarely durable after 
withdrawal of therapy (5, 26, 47, 56). Alternative approaches to targeting HBV are being 
investigated, with particular emphasis being placed on antiviral gene therapy.  
 
1.1.1 HBV genome structure 
HBV is a member of the Hepadnaviridae family of hepatotropic viruses. The family 
consists of two genera, namely the Orthohepadnaviruses and the Avihepadnaviruses. 
Orthahepdnaviruses infect squirrels and woodchucks from the Sciuridae family and a 
variety of primates, including Homo sapiens, from the Lorisidae family, whilst 
Avihepadnaviruses infect ducks, herons and geese.  
 
The viral genome is enclosed within the nucleocapsid and comprises a 3.2 kilobase (kb) 
partially double stranded (pds) relaxed circular (rc) deoxyribonucleic acid (DNA), which is 
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converted into covalently closed circular (ccc) DNA during active infection (4, 23) and four 
partially overlapping open reading frames (ORFs) (Figure 1.1).  
 
The X ORF encodes for the 0.9 kb Hepatitis B X (HBx) viral transcript. The functioning of 
the X protein is not clearly understood, however it is known to be required for active 
infection and is a possible mediatior involved in the debilitating hepatocarcinomas 
associated with chronic HBV infection (59). In 2010, Bouchard and colleagues (17) 
demonstrated the involvement of HBx in the regulation of cell proliferation and HBV 
replication. 
 
The polymerase ORF encodes for viral polymerase, which has reverse transcriptase 
activity required for the replication of the virus.  
 
The precore/core ORF contains two in phase transcriptional start codons, generating two 
viral transcripts of ~3.5 kb. The precore region of the precore/core gene encodes an 
additional 29 nucleotides (nt) at the N-terminal domain of the protein (12). The viral 
transcripts encode the viral capsid protein or hepatitis B core antigen (HBcAg), which 
assemble into the viral core particle. 
 
The fourth ORF contains three in phase transcriptional start codons, which generate the 
glycoproteins of the viral envelope. The smallest surface protein, which is 226 amino acids 
in length, is encoded by the surface domain of the ORF. The Pre-S2 and surface region of 
the ORF together code for the middle (M) protein. The large (L) surface protein (389 amino 
acids) is encoded for by the Pre-S1, Pre-S2 and surface domains of the ORF. A 
comprehensive review of the viral transcripts has been previously discussed (12, 47).  
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Figure 1.1: Map of hepatitis B virus genome.  
The inner four arrows represent the four ORFs which encode the viral proteins of HBV. The viral 
transcripts are represented by the four outer arrows and terminate at a unique site on the 3’ end. 
The figure was adapted from previously published work (5). 
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1.1.2  Replication of HBV 
The inability of the virus to infect cells in vitro and the lack of convenient animal models 
that are infectable by the virus has limited analysis of early events in the life cycle of HBV. 
As a consequence although it is known that hepatocytes are the primary site of infection 
the precise mechanism and receptor the virus uses to attach and enter the cells remains 
unknown. Nevertheless, investigations have defined two epitope regions within the HBsAg 
involved in attaching the virion to the hepatocyte. The first epitope occurs within the Pre-
S1 region between amino acids 21 to 47 (40, 41) and the second region occur within the 
small HBsAg and is predicted to enhance the attachment of the virion to the cell (43).  
 
Post virion adherence to the hepatocyte, the pds rcDNA viral genome, which is comprised 
of the long minus strand (- strand) and short plus strand (+ strand) (Figure 1.1) is 
transported to the nucleus. The genome is transcribed into cccDNA, which acts as the 
template for the transcription of viral mRNAs (12, 47). The pre-genomic RNA (pgRNA) 
transcript is 3.5 kb in length, which is longer than genome and forms the basis for 
synthesis of the (-) strand by reverse transcription. Synthesis of a small primer sequence is 
initialised by the viral Pol promoter at the 5’ end. The primer-polymerase complex 
translocates to a homolgous region at the 3’ end of the pgRNA and begins reverse 
transcribing the viral transcript generating the (-) strand (Figure 1.2). The primer-
polymerase complex again translocates to the 5’ end of the synthesised (-) strand and 
begins synthesising the (+) strand. (12).  
 
The synthesis of the viral genome from an RNA intermediate (i.e. the pgRNA) allows viral 
replication to be directly targeted by RNAi. In contrast established cccDNA may not be 
susceptible to RNAi-mediated silencing and as a consequence limit efficacy of RNAi-
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Figure 1.2: HBV replication cycle.  
The virion attaches to the hepatocyte and is internalised into the cytoplasm of the cell. The viral genome is transloacated to the nucleus and 
synthesised into cccDNA. The pgRNA viral transcript is synthesised to form the (-) strand and following translocation of the polymerase primer 
complex, the (+) strand is synthesised. The virion is formed and buds out through the endoplasmic reticulum. 
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based therapeutics (49). The overlapping nature of the HBV genome also makes it a 
perfect target for RNAi therapeutics as there is little chance for the occurrence of 
mutations within the genome. Furthermore, because the viral transcripts overlap, the 
targeting of a single site within an overlapping region silences multiple viral transcripts.  
  
1.2 The endogenous RNA interference pathway 
The RNA interference pathway is an evolutionary conserved cellular pathway involved in 
post-transcriptional gene silencing. In 1998, Fire et al (16) coined the term RNA 
interference (RNAi) to describe the silencing of genes by dsRNA. The mechanism of RNAi, 
however, had been observed in plants almost a decade earlier by two different groups 
attempting to increase the hue in petunias by introducing a transgene (38, 50). Notably, 
the genetically altered petunias were either variegated purple and white or complete white. 
There was no forthcoming explanation for this phenomenon, until the discovery of RNAi in 
Caenorhabitis elegans (16). 
 
In 2001, Tuschl et al (13) demonstrated the suppression of target Luciferase using 21 nt 
small interfering RNAs (siRNAs). Evidentially, this was the principal investigation that 
showed RNAi-mediated gene silencing in mammalian cell culture. The endogenous RNAi 
pathway (Figure 1.3) begins with the transcription of long principal transcripts termed 
primary miRNAs (pri-miRNAs) by RNA Polymerase II (Pol II). The pri-miRNAs are 
recognised and stabilised by Digeorge syndrome critical region 8 (DGCR8) (55). DGCR8 
directs the cleavage of the pri-miRNAs into ~70 nt pre-cursor miRNAs (pre-miRNAs) with a 
2 nt overhang at the 3’ end, by RNaseIII Drosha (32, 55). The pre-miRNAs are exported 
from the nucleus into the cytoplasm by Exportin-5 (31). The PAZ domain of the RNaseIII 
enzyme Dicer recognizes the 2 nt overhang of the pre-miRNAs which are subsequently 
processed into ~22 nt mature miRNAs by Dicer/TAR RNA binding protein (TRBP) (33). 
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The mature miRNAs are incorporated into the RNA-induced silencing complex (RISC) and 
are unwound by an adenosine triphosphate (ATP)-dependent helicase into two 
independent strands (anti-guide and guide), which are known as siRNAs. Argonaut 2 (Ago 
2) selects the strand complementary to the messenger RNA (mRNA) target, subsequently 
binding the strand to the target. Complete binding of the guide strand to the mRNA target 
through Watson-Crick base pairing causes translational repression and silencing of the 
target gene. Alternatively, incomplete binding of a guide strand due to mismatched base 
pairs between the guide strand and mRNA target results in degradation of the target (36, 
57). It has since been shown that miRNAs play an important role in various biological 
processes, including differentiation and proliferation of the cell (10, 24, 54). 
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Figure 1.3: The endogenous RNAi pathway.  
Pri-miRNAs are transcribed from DNA by Pol II, anchored by DGCR8 and cleaved by Drosha into a pre-miRNA. The pre-miRNAs are exported out 
of the nucleus and into the cytoplams by exportin-5. Cleavage of the pre-miRNA by Dicer generates a 22 nt siRNA duplex. An ATP-dependent 
helicase unwinds the duplex, and Ago2 incorporates the guide strand into RISC. Complete complementarity of the guide strand to the mRNA target 
causes degradation of the target gene, whereas incomplete complementarity causes translational suppression of the target gene. 
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1.2.1 Harnessing the RNAi pathway through exogenous RNA mimics 
The endogenous RNAi pathway may be harnessed as a novel approach for antiviral gene 
therapy and research based therapeutics, due to the target specificity of dsRNAs (~19-25 
nt). There are three different approaches involved in exploiting the endogenous RNAi 
pathway through the introduction of exogenous RNAi intermediates, which mimic either the 
pri-miRNA, pre-miRNA or mature miRNA components of the endogenous pathway (Figure 
1.4).  
 
1.2.1.1  Pri-miRNA mimics 
Pri-miRNA mimics are designed to incorporate the effecter sequence within the pre-
miRNA stem region ( 22 nt). The structural design of the pre-miRNA is critical when 
generating a mimic because the secondary folding of the pre-miRNA mimic should be 
maintained as to be as identical as possible to that of the pre-miRNA. Pol II transcribes 
natural endogenous pri-miRNAs within the nucleus of a cell before entering the RNAi 
pathway. Pri-miRNA mimics are inserted downstream of a Pol II promoter contained within 
an expression vector. Post transportation of the vector into the nucleus of the cell, the pri-
miRNA mimics are transcribed and processed by the endogenous microprocessor 
complex (Drosha and DGCR8) and exported via the RNAi pathway.  
 
1.2.1.2  Pre-miRNA mimics  
Exogenous pre-miRNA mimics are generally referred to as short hairpin RNAs (shRNAs). 
These mimics represent ‘processed pri-miRNAs’ and are comprised of only the effecter 
sequence complementary to the mRNA target incorporated into the 5’ stem region and a 
loop and have no flanking sequences. As with expressed pri-miRNA mimics, expressed 
shRNAs require DNA-dependent RNA polymerase to drive transcription. RNA Pol III 
promoters are generally chosen to drive the expression of shRNAs as these promoters 
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initiate transcription at a definitive start site, adjacent to which the shRNAs are located. 
Transcribed shRNAs enter the RNAi pathway by being exported out of the nucleus and 
into the cytoplasm for Dicer processing.  
 
1.2.1.3  miRNA Mimics 
The final way in which to exploit the endogenous RNAi pathway is through the introduction 
of siRNAs. Comprised of only the effecter and complementary sequence, these small 
dsRNAs can be transduced directly into the cytoplasm of the cell. Selection of the guide 
strand by Ago2 and incorporation into the RISC complex proves a simple and effective 
approach in exploiting the RNAi pathway.  
 
1.2.1.4  Exploitation of the RNAi pathway to targeting HBV  
Exploitation of the RNAi pathway as a tool for powerful and specific gene silencing has 
initiated investigations into the utilisation of expressed or synthetic effecter sequences for 
therapeutic purposes. The compact genome and limited mutability of HBV has established 
the virus as an excellent candidate for RNAi-based therapy. Previous studies have 
indicated that gene therapy approaches (eg ribozyme therapy (44, 52, 53)) may be 
effective as an HBV therapeutic. RNAi offers a powerful to for specifically silencing viral 
replication. Subsequent development of a potent RNAi construct may in time lead to 
therapeutics effective in managing chronic HBV infection (5, 37). 
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Figure 1.4: Exploitation of the RNAi pathway.  
(A) Pri-miRNA mimics are transcribed within the nucleus and are processed in the same manner as endogenous pri-miRNAs. (B) pre-miRNA 
mimics are transcribed within the nucleus and exported into the cytoplasm by exportin-5. (C). Synthetic miRNAs can be transduced directly into the 
cytoplasm as a siRNA duplex. Complete complementarity of the mimic guide strand to the mRNA target causes degradation of the target gene, 
whereas incomplete complementarity causes translational suppression of the target gene. 
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1.3 RNA polymerase promoters 
Eukaryotes maintain transcriptional control of genes within the nuclei through the 
functioning of three different types of DNA-dependent RNA polymerases namely Pol I, Pol 
II and Pol III (7). Gene transcription by Pol I is limited to the synthesis of large ribosomal 
RNA (rRNA). Pol III synthesises 5S RNA and transfer RNA (tRNA). Pol II, however, is 
capable of transcribing an extensive selection of genes as it is responsible for the 
synthesis of mRNA. 
 
1.3.1 RNA polymerase II (Pol II) promoters 
RNA Pol II is known to transcribe a vast range of mRNAs within the cell. Initial hypotheses 
speculated Pol III promoters to drive synthesis of miRNA genes, however in 2004, Lee et 
al (33) identified the regulatory elements to be Pol II promoters. Investigations have since 
demonstrated that RNA Pol II promoters can direct gene silencing to a particular cell or 
tissue, whereas Pol III promoters lack cell or tissue specificity (58). 
 
1.3.2 RNA polymerase III (Pol III) promoters 
Pol III promoters are robust transcriptional activators, which are divided into three classes 
based upon their structural arrangements. Class I Pol III and class II Pol III promoters 
contain internal control regions (promoter elements) situated downstream of the 
transcripton start site. Class III Pol III promoters differ from those of class I and class II in 
that the genes do not contain internal promoter elements, but do contain three promoter 
elements situated upstream of a defined transcriptional start site (8, 35, 45, 46). The 
promoter elements, namely the distal sequence element (DSE), proximal sequence 
element (PSE) and TATA box are required for gene expression, and the structural layout 
of the class III Pol III promoter closely resembles that of Pol I and Pol II promoters (Figure 
1.5).
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Figure 1.5: Gene structure of the U6, H1 and tRNA.  
(A and B) U6 and H1 are class III Pol III promoters and share a similar gene structure, although H1 is smaller. The distal sequence element 
(DSE)and  proximal sequence element (PSE) are found downstream of the TATA box, which initiates transcription at a definative start site (+1). (C) 
The tRNA gene is a class II Pol III promoter. Transcription begins within the structural genes of the tRNA, trascribing precursor tRNAs.  
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1.3.3 U6, H1 and tRNALys3 RNA Pol III Promoters  
The gene encoding U6 small nuclear RNA (snRNA) has a characteristically different 
structure in comparison to the remaining eleven snRNAs found within the U series. In 
1986, several of the structural differences within the U6 snRNA prompted Pederson et al 
(29) to hypothesise that U6 snRNA was not sythesised by Pol II, but by an alternate 
polymerase. The investigation demonstrated that Pol III was responsible for the 
transcription of U6 snRNA. This initial finding was further supported by the identification 
that transcription of U6 snRNA was terminated by a series of thymine nucleotides (poly-T 
tail) at the 3’ end. This particular nature of transcriptional termination was initially identified 
for 5S rRNA, which is known to be under the transcriptional control of a Pol III promoter 
(3). 
 
In 1989, Baer et al (1) assessed the structure and transcription of H1 RNA. Structurally H1 
was found to be compact and the promoter elements required for transcription located 
upstream of the transcription start site (Figure 1.3). As discovered within U6 snRNA, the 
structural genes of H1 RNA were characteristic of both Pol II and Pol III transcripts, but 
transcription was synthesised by Pol III (1). 
 
tRNA genes are grouped within class I of Pol III promoters. The transcriptional start site of 
the promoter occurs within the structural gene of tRNAs and are smaller when compared 
to class III RNA Pol III promoters (43).  
 
1.4 Utilising RNA Pol II and RNA Pol III promoters for RNAi 
Pol III promoters are capable of rapidly synthesising shRNAs, which is advantageous in 
directing rapid gene silencing (58). Specific Pol III promoters, however, are more effective 
at transcribing RNA than other promoters within the same class. This is particularly evident 
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between U6 and H1, where H1 transcribes at a lower rate when compared to U6. Although 
expressing high levels of RNAs, Pol III promoters lack the ability to successfully transcribe 
RNAs of greater nucleotide length whereas Pol II is perfectly capable. Furthermore, Pol II 
promoters are capable of spatial and temporal control of gene expression at a localised 
tissue or cell, which is important in site-directed antiviral gene therapy (33, 58). 
 
There are three important requirements to consider when generating effecter cassettes for 
antiviral gene therapy. Firstly, dsRNA, should be potent in its ability to actively silence the 
target mRNA. Secondly, the level of expression of the dsRNA is important, as the 
concentration of the effecter cassette should be low but optimally expressed. Finally, there 
should be no off-target or toxic effects associated with the delivery and expression of an 
effecter cassette. This is of particular importance based on the initial findings in which 
Grimm et al (22) assessed the effects associated with the long-term expression of shRNAs 
in mice. Briefly, adeno-associated viral (AAV) vectors that express anti-HBV shRNAs were 
administered to mice. Dose-dependent liver injury was noted in 73% of the mice, of which 
63% died. It was determined that the exogenous shRNAs were competing with 
endogenous pre-miRNAs for the cellular factors required for processing and exporting of 
RNAs, subsequently saturating the endogenous miRNA pathway within the hepatocytes.  
 
Previous investigations have demonstrated that efficacy of U6 promoters to transcribe 
effecter sequences at higher levels when compared to H1, silencing a variety of different 
targets, in vitro and in vivo, through RNAi (8). Furthermore, tRNAVal, tRNALys3 and U6 
promoter-driven shRNA expression cassettes have demonstrated a comparable efficacy of 
target knockdown between the promoters (27, 45, 46). These preliminary investigations 
have initiated suggestions that lower level transcription has a particular importance in 
RNAi as the targets are optimally silenced and no off-target or toxic effects (28, 46). 
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Recently, Kay et al (18) demonstrated that a shRNA expression cassette driven by a liver 
specific Pol II promoter functions optimally in silencing HBV in vitro and in vivo.   
 
1.5  Export and processing 
The export of transcribed tRNAs, rRNAs and mRNAs from the nucleus to the cytoplasm 
occurs through the nuclear pore complexes (NPC) (34). The shuttling of components is 
mediated by the transport receptors importin and exportin, which differ depending upon the 
macromolecule being transported (30, 34). 
 
Pre-miRNAs, which are processed from pri-miRNAs by the RNAse III enzyme Drosha are 
transported out of the nucleus and into the cytoplasm via the transport receptor exportin-5. 
The cleavage by Drosha produces a characteristic short 3’ overhang, which is recognised 
by exportin 5 (48). Export of the pre-miRNAs into the cytoplasm precedes Dicer 
processing and incorporation of duplexes into RISC.   
 
Exportin-t and RanGTP, which bind to tRNA to form a trimeric complex, assist in the 
shuttling of the tRNALys3 from the nucleus to the cytoplasm. After transportation from the 
nucleus, the complex is disassembled within the cytoplasm (30, 34). Prior to the export, 
precursor tRNAs (pre-tRNAs) undergo particular post-transcriptional modifications to 
become functionally active tRNAs. The modifications, which include trimming of the 3’ and 
5’ ends, nucleoside alterations and the addition of a 3’CCA (34) are carried out to stabilise 
the conformation of the clover-leaf secondary structures and to assist in the activities 
performed by tRNAs (8, 25). The precise mechanism involved in processing tRNALys3-
shRNA is remains unclear, however Scherer et al (45) have proposed that the 3’ tRNase 
(tRNase ZL) is responsible for cleaving tRNALys3-shRNA. 
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1.6 Aims of the investigation 
The primary aim of the investigation was to assess whether four different promoters could 
successfully transcribe anti-HBV effecter sequences capable of rapidly and effectively 
inhibiting HBV. The RNA Pol III (U6, H1 and tRNALys3) and RNA Pol II (CMV) promoters 
were used to drive the expression of five different RNAi effecter sequences. Furthermore, 
the project aimed to analyse whether expression from the H1, tRNALys3 and CMV 
promoters is less than that from U6 promoter expression, whilst maintaining the same 
degree of knockdown.  
 
The efficacy of these shRNAs expression cassettes and pri-miRNA shuttles to knockdown 
their targets at varying concentrations would provide an insight into establishing the lowest 
possible dosage at which the shRNA or miRNA could optimally function, which is of 
importance in creating a therapeutic tool to actively target HBV. 
 
In conclusion, the project aims to provide an insight into the functioning of shRNA and 
miRNA expression cassettes driven by Pol II and Pol III promoters and the targeting of 
HBx at different sites, without causing any resultant off targeting or saturation effects. 
Ultimately, the findings of the investigation would assist in aiding research into developing 
treatment of HBV utilising antiviral therapeutics through RNA interference. 
. 
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2  MATERIALS AND METHODS 
2.1  Construction of H1 shRNA Expression Cassettes 
2.1.1.  Generation of the H1 promoter 
The full H1 promoter described by Chen and colleagues (11) was engineered to 
incorporate an EcoRI and a SpeI restriction site at the 5’ end. The H1 forward (5’-GAT 
CGA ATT CAC TAG TGA ACG CTG ACG TCA TCA A-3’) and primers (5’-GGA TCC GTG 
GTC TCA TAC AGA ACT TAT AAG ATT CCC AAA TC-3’) were synthesised using 
standard phosphoramidite chemistry (IDT, IA, USA). The lyophilised oligonucleotides were 
resuspended as 100 µM stocks and 15 µM working stocks were prepared. The H1 
promoter was amplified by polymerase chain reaction (PCR) in a final reaction volume of 
25 µl containing 100 ng H1 human genomic DNA; 15 pmol H1 forward primer; 15 pmol H1 
reverse primer; 2.5 mM dNTP mix; 0.25 U TripleM™ Taq polymerase and was carried out 
in 1× high fidelity buffer using the TripleM™ High Fidelity PCR Kit (Eppendorf, Germany). 
The PCR was programmed to run with an initial denaturation at 94°C for 5 minutes with 
ten cycles of touchdown PCR (denaturation at 94°C for 10 seconds; annealing at 67°C for 
10 seconds and elongation at 72°C for 10 seconds, with the annealing temperature 
decreasing by 1 degree with every cycle). Thereafter fourteen cycles of standard PCR 
(denaturation at 94°C for 20 seconds; annealing at 57°C for 20 seconds and elongation at 
72°C for 45 seconds) and a final elongation step at 72°C for two minutes and thirty 
seconds followed (Eppendorf Mastercycle Gradient, Germany). The size of the DNA 
fragment amplified by PCR was verified using agarose gel electrophoresis (Appendix A.1). 
The desired band was excised from the gel and then purified using the MinElute™ Gel 
Extraction Kit (Qiagen, Germany) according to the manufacturer’s instructions (Appendix 
A.2). The purified H1 promoter DNA was used as the template for generating the H1 
shRNA expression cassettes. 
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2.1.2 Construction of H1 shRNA expression cassettes 
Primers (Table 2.1) were designed to generate H1 shRNA expression cassettes equivalent 
to the previously described U6 shRNA cassette (5).The shRNA expression cassettes were 
constructed using a two-step PCR reaction (Figure 2.1) (6). Reverse primers for the first 
round of PCR were designed to incorporate the sense strand, loop and four nucleotides of 
the antisense strand for shRNA 5, shRNA 6, shRNA 8, shRNA 9 and shRNA 10 (5). The 
expressed shRNA sequences were designed to target nucleotides 1575-1599, 1580-1604, 
1678-1692, 1774-1788 and 1863-1877 of HBV (Genbank Accession Number J02203.1). 
Base wobbles were inserted into the sense strand to prevent errors from occurring during 
PCR, subsequently aiding in cloning. The oligonucleotides were synthesised using 
standard phosphoramidite chemistry (IDT, IA, USA) and prepared as previously described 
(Section 2.1.1). Reverse primers for the second round of PCR were designed to 
incorporate the remaining sequence of the antisense strand as well as the termination 
signal to the amplicon from the first round PCR. The H1 forward primer (5’-GAT CGA ATT 
CAC TAG TGA ACG CTG ACG TCA TCA A-3’) was used in both rounds of the two-step 
PCR reaction. The first round PCR was prepared in a final reaction volume of 25 µl 
containing 100 ng H1 promoter template DNA; 15 pmol H1 forward primer; 15 pmol 
shRNA N.1 (where N denotes the hairpin i.e. 5, 6, 8, 9, or 10) round one reverse primer; 4 
mM dNTP mix; 0.75 U GoTaq® Polymerase; 1 mM MgCl2 and was carried out in 1× 
GoTaq® Flexi Buffer using the GoTaq® Flexi DNA Polymerase Kit (Promega, WI, USA). 
The PCR cycle was carried out as previously described (Section 2.1.1) and the sizes of 
the amplified DNA fragments verified using agarose gel electrophoresis. The desired DNA 
bands were 
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Table 2.1: The reverse primers designed for the construction of H1 shRNA expression cassettes using two-step PCR 
 
shRNA Round Sequence 
H1 shRNA 5 
1 
2 
5’TCTGTGACAGGAAGCAGAGGCGAAGCAAAGCGCACACGACGGATCCGAGTGGTCTCATAC 3’ 
5’CCCAGATCTACGCGTAAAAAACCGTGTGCACTTCGCTTCACCTCTGTGACAGGAAGCAGAG 3’ 
H1 shRNA 6 
1 
2 
5’ACGTTGACAGGAAGATGTGTAGAGGTGAAGCGAGGTGTACGGATCCGAGTGGTCTCATAC 3’ 
5’CCCAGATCTACGCGTAAAAAATGCACTTCGCTTCACCTCTGCACGTTGACAGGAAGATGTG 3’ 
H1 shRNA 8 
1 
2 
5’AGGCTGACAGGAAGGCTTCAAGGTTGGTTGTTGACGTTGCGGATCCGAGTGGTCTCATAC 3’ 
5’CCCAGATCTACGCGTAAAAAACAATGTCAACGACCGACCTTGAGGCTGACAGGAAGGCTTC 3’ 
H1 shRNA 9 
1 
2 
5’TGGTTGACAGGAAGACTAATTTGTGCCTACAGCTTCTTACGGATCCGAGTGGTCTCATAC 3’ 
5’CCCAGATCTACGCGTAAAAAATAGGAGGCTGTAGGCATAAATTGGTTGACAGGAAGACTAA 3’ 
H1 shRNA10 
1 
2 
5’TTGGTGACAGGAAGCCAAAGCACAACTCGGAGGCTCGAACGGATCCGAGTGGTCTCATAC 3’ 
5’CCCAGATCTACGCGTAAAAAATTCAAGCCTCCAAGCTGTGCCTTGGTGACAGGAAGCCAAG 3’ 
The H1 promoter binding sequences are italicised, with primer overlapping sequences in bold. The hairpin loop encoding 
sequence is underlined and the base wobbles within the sense strand are double underlined 
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excised from the gel and purified using the MinElute™ Gel Extraction Kit. The purified first 
round PCR product was used as template in the second round of PCR for the generation 
of the complete H1 shRNA cassettes. 
 
The second round PCR was prepared in a final reaction volume of 50 µl containing 100 ng 
first round PCR product DNA; 15 pmol H1 forward primer; 15 pmol H1 shRNA N.2 round 
two reverse primer; 10 mM dNTP mix; 0.25 U TripleM™ Taq polymerase and was carried 
out in 1× High Fidelity buffer using the TripleM™ High Fidelity PCR Kit. The PCR cycle 
was programmed as previously described (Section 2.1.1) and the size of the amplicons 
verified by agarose gel electrophoresis. The desired DNA bands were excised and purified 
using the MinElute™ Gel Extraction Kit. 
 
2.1.3  Cloning of H1 shRNA expression cassettes 
The H1 shRNA expression cassettes were inserted into the PCR cloning vector pTZ57R/T 
(InsT/Aclone™ Fermentas, MD, USA). Ligation reactions were prepared in a final reaction 
volume of 20 µl containing 300 ng H1 shRNA PCR product; 0.165 µg pTZ57R/T; 7.5 U T4 
DNA ligase and was carried out in 1× ligation buffer (Fermentas, MD, USA) and incubated 
overnight at room temperature. The ligation mixtures were used to transform chemically 
competent Escherichia coli (E. coli) DH5-α cells (Invitrogen, CA, USA) (Appendix A.3). 
Transformed bacteria were plated onto Luria-Bertani (LB) agar plates (Appendix A.4) 
containing 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) (Appendix A.5) 
and isopropyl thiogalactoside (IPTG) (Appendix A.6) and incubated overnight at 37°C. 
Bacteria transformed with the pTZ57R/H1 shRNA plasmids were identified using 
blue/white screening (Appendix A.7). Five clones of each H1 shRNA were picked, 
inoculated in 4 ml LB and incubated at 37°C overnight in a shaking incubator. The H1 
shRNA plasmid DNA (pDNA) was purified from 
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Figure 2.1: Generation of the H1 shRNA expression cassettes.  
The H1 shRNA expression cassettes were constructed in a two-step PCR and ligated into the 
cloning vector pTZ57R/T. (A) The first round amplified the H1 promoter (purple), the sense strand 
(pink) the loop (orange) and 4 nucleotides of the antisense strand (red). (B) The second round of 
PCR amplified the first round product and completed the amplification of the antisense strand and 
poly-T termination site. (C) The H1 shRNA expression cassette was ligated into pTZ57R/T between 
the EcoRI and BglII restriction sites. 
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the bacterial cultures using the High Pure Plasmid Isolation Kit (Roche, Germany) 
according to the manufacturer’s instructions (Appendix A.8). 
 
2.1.4  Orientation of H1 shRNA Expression Cassettes 
The orientation of the individual H1 shRNA cassettes inserted into the multiple cloning site 
(MCS) of pTZ57R/T was determined using an EcoRI (Fermentas, MD, USA) restriction 
digestion in a final reaction volume of 20 µl containing 10 U EcoRI; 1700 ng pTZ57R/H1 
shRNA and was carried out in 1× EcoRI buffer. The restriction digest reactions were 
incubated for one hour at 37°C. The DNA fragments from the digested clones were 
subjected to agarose gel electrophoresis. The clones were sequenced using automated 
cycle sequencing using the universal M13 forward (5'-GTA AAA CGA CGG CCA G-3') and 
reverse (5'-CAG GAA ACA GCT ATG AC-3') primers (Inqaba, Pretoria, RSA) (Appendix 
A.9). The chromatograms were analysed using FinchTV™ version 1.4.0 (Geospiza Inc. 
WA, USA). 
 
2.2  Generation of an H1 Mock Expression Cassette 
An H1 Mock expression cassette was designed as a control against the H1 shRNA 
expression cassettes. The H1 Mock reverse primer (5’-GAT CAA AAA ACG GAT CCG 
AGT GGT-3’) was designed to contain only the termination signal. The oligonucleotide was 
synthesised using standard phosphoramidite chemistry (Inqaba, Pretoria, RSA) and 
prepared as previously described (Section 2.1.1). The PCR was prepared in a final 
reaction volume of 20 µl containing 500 ng H1 promoter template DNA; 15 pmol H1 
forward primer; 15 pmol H1 Mock reverse primer and 2.5 µl MasterMix™ (Promega, WI, 
USA). The PCR cycle was performed as previously described (Section 2.1.1) and the size 
of the amplified DNA fragment verified using agarose gel electrophoresis. The DNA band 
was excised from the gel and purified using the MinElute™ Gel Extraction Kit. The H1 
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Mock expression cassette was inserted into the PCR cloning vector pTZ57R/T as 
described in Section 2.1.3. The successful insertion of the H1 Mock expression cassette 
into pTZ57/T was assessed by colony PCR. Briefly, ten colonies were selected and 
resuspended in 10 µl sterile water. The PCR was prepared in a final reaction volume of 20 
µl containing 5 µl of the resuspended clone; 10 pmol M13 forward primer; 10 pmol H1 
reverse primer and 12.5 µl MasterMix™ (Promega, WI, USA). The PCR was programmed 
to run with an initial denaturation at 94°C for 5 minutes with thirty cycles of standard PCR 
(denaturation at 94°C for 20 seconds; annealing at 57°C for 20 seconds and elongation at 
72°C for 45 seconds) and a final elongation step at 72°C for two minutes and thirty 
seconds followed (Eppendorf Mastercycle Gradient, Germany). The size of the clones was 
verified by agarose gel electrophoresis. The selected clone was inoculated in 4 ml LB and 
incubated at 37°C overnight in a shaking incubator and the pDNA was purified from the 
bacterial cultures using a standard alkaline lysis plasmid isolation protocol (Appendix 
A.10). 
 
2.3 tRNALys3 shRNA Expression Cassettes 
2.3.1  Preparation of tRNALys3 shRNAs 
The generation of the p901-1 plasmid has been previously described (45) Briefly, the 
tRNALys3-NruI promoter sequence was generated by PCR and cloned into pBluescript as a 
SalI/HindIII fragment. The p901-1 tRNALys3 vector provides a backbone for the direct 
insertion of annealed shRNA encoding oligonucleotides between the NruI restriction site 
within the tRNALys3 promoter sequence and the PstI restriction site of pBluescript. The 
tRNALys3 shRNA oligonucleotides (Table 2.2) were designed to be complementary to each 
other and anneal as dsDNA with a 5’ blunt end and a 3’ overhang compatible with a PstI 
created sticky end. Oligonucleotides were synthesised using standard phosphoramidite 
chemistry (IDT, IA, USA). Lyophilised oligonucleotides were resuspended to 100 µM 
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stocks and individually phosphorylated in a final reaction volume of 20 µl containing 200 
pmol oligonucleotide; 1 mM ATP; 5 U T4 polynucleotide kinase (PNK) (Promega, WI, 
USA) and was carried out in 1× PNK buffer for one hour at 37°C. The complementary 
phosphorylated oligonucleotides were mixed to a final concentration of 5 µM and the PNK 
heat inactivated at 75°C for ten minutes. The heating block was removed from the 
chamber and cooled slowly allowing the oligonucleotides to anneal. The annealed 
oligonucleotides were diluted 25-fold (200 nM) and stored at -20°C until required. 
 
2.3.2  Directional cloning of tRNALys3 shRNA expression sequences 
The tRNALys3 shRNA sequences were inserted into p901-1 by directional cloning (Figure 
2.2). The sequence of the p901-1 backbone was confirmed by a double restriction digest 
with DraI and SalI (Fermentas, MD, USA) in a final reaction volume of 20 µl containing 10 
U DraI; 10 U SalI; ~1000 ng p901-1 and was carried out in 1× Buffer Tango for one hour at 
37°C.  
 
To clone the tRNALys3 shRNA sequences into the p901-1 vector, the vector was subjected 
to a double restriction digest with NruI and PstI (Fermentas, MD, USA) in a final reaction 
volume of 30 µl containing 10 U NruI; 10 U PstI; 2000 ng p901-1 and was carried out in 1× 
Buffer R at 37°C for two hours. The NruI/PstI digested plasmid was dephosphorylated 
using calf intestinal phosphatase (CIP) (New England Biolabs, UK) in a total reaction 
volume of 40 µl containing 10 U CIP and was carried out in 1× CIP buffer at 37°C for one 
hour. The reaction mix was incubated at 75°C in a dry heating block for ten minutes. The 
dephosphorylated p901-1 plasmid fragment was subjected agarose gel electrophoresis, 
excised and purified using the MinElute™ Gel Extraction Kit. The purity of the 
dephosphorylated p901-1 vector DNA was verified using agarose gel electrophoresis. The 
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DNA concentration (ng/µl) of dephosphorylated p901-1 was measured at 260 nm 
(NanoDrop ND-1000 Spectrophotometer, DE, USA). 
 
The dephosphorylated backbone and annealed dsDNAs were ligated in a final reaction 
volume of 20 µl containing 50 ng dephosphorylated p901-1; 0.5 nM dsDNA (tRNALys3 
shRNA 5, 6, 8, 9 or 10); 7.5 U T4 DNA ligase and was carried out in 1× ligation buffer 
(Fermentas, MD, USA) at 16°C for 24 hours. Ligation mixtures were used to transform 
chemically competent E. coli (DH5-α cells). Transformed bacteria were plated onto LB 
agar plates containing ampicillin and incubated overnight at 37°C. Three colonies from 
each tRNALys3 shRNA plate were picked, inoculated in 4 ml LB and incubated at 37°C 
overnight in a shaking incubator. The pDNA was purified from the bacterial cultures using 
the High Pure Plasmid Isolation Kit. 
 
2.3.3  Confirmation of tRNALys3 shRNA inserts 
The p901-1 tRNALys3 shRNA clones were subjected to a double restriction digest with 
BamHI and XhoI (Fermentas, MD, USA) in a final reaction volume of 20 µl containing 10 U 
BamHI; 10 U XhoI; ~1000 ng tRNALys3 shRNA clones and was carried out in 1× Buffer O at 
37°C for one hour. The insertion of the shRNA encoding sequences was detected using 
agarose gel electrophoresis. The clones were sequenced using automated cycle 
sequencing. The chromatograms were analysed using FinchTV™ version 1.4.0 and the 
sequences aligned using VectorNTI™ version 10.1.1 AlignX™ application. 
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Table 2.2: Oligonucleotides for the generation of tRNALys3 shRNA expression cassettes  
 
shRNA Primer Sequence 
tRNALys3 
shRNA 5 
F 
R 
5’GGCGTCGTGTGCGCTTTGCTTCGCCTTTGTGTAGGGTGAAGCGAAGTGCACACGGTTTTTTGCA 3’ 
5’AAAAACCGTGTGCACTTCGCTTCACCCTACACAAAGGCGAAGCAAAGCGCACACGACGCC 3’ 
tRNALys3 
shRNA 6 
F 
R 
5’GGCGTACACCTCGCTTCACCTCTACTTTGTGTAGGCAGAGGTGAAGCGAAGTGCATTTTTTGCA 3’ 
5’AAAAATGCACTTCGCTTCACCTCTGCCTACACAAAGTAGAGGTGAAGCGAGGTGTACGCC 3’ 
tRNALys3 
shRNA 8 
F 
R 
5’GGCGCAACGTCAACAACCAACCTTGTTTGTGTAGCAAGGTCGGTCGTTGACATTGTTTTTTGCA 3’ 
5’AAAAACAATGTCAACGACCGACCTTGCTACACAAACAAGGTTGGTTGTTGACGTTGCGCC 3’ 
tRNALys3 
shRNA 9 
F 
R 
5’GGCGTAAGAAGCTGTAGGCACAAATATTGTGTAGATTTATGCCTACAGCCTCCTATTTTTTGCA 3’ 
5’AAAAATAGGAGGCTGTAGGCATAAATCTACACAATATTTGTGCCTACAGCTTCTTACGCC 3’ 
tRNALys3 
shRNA 10 
F 
R 
5’GGCGTTCGAGCCTCCGAGTTGTGCTATTGTGTAGGGCACAGCTTGGAGGCTTGAATTTTTTGCA 3’ 
5’AAAAATTCAAGCCTCCAAGCTGTGCCCTACACAATAGCACAACTCGGAGGCTCGAACGCC 3’ 
The sequence encoding the tRNA
Lys3
 acceptor arm sequence is italicised and the base wobbles within the sense strand are double-
underlined. The loop is underlined and the A → T base change in shRNA 9 and shRNA 10 are underlined and italicised. The sequence 
encoding the antisense strand is indicated bold. (F) Forward; (R) Reverse. 
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Figure 2.2: Insertion of shRNA encoding sequences into p901-1.  
Two complementary oligonucleotides were annealed to create the shRNA encoding sequence, which was subsequently ligated into the digested 
p901-1 between the PstI and NruI restriction sites. 
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2.4  Generation of tRNA+1 mock expression cassette 
The tRNALys3 Mock expression cassette was designed to incorporate only the termination 
signal. The tRNALys3 Mock forward (5’-GGC GTT TTT TCT GCA GCC CGG GGG ATC 
CAC TAG TTC TAG AGC-3’) and tRNALys3 Mock reverse (5’-GGC CGC TCT AGA ACT 
AGT GGA TCC CCC GGG CTG CAG AAA AAA CGC C-3’) oligonucleotides were 
designed to be complementary to each other and anneal as dsDNA with a 5’ blunt end and 
a 3’ overhang compatible with a PstI created sticky end. Oligonucleotides were 
synthesised using standard phosphoramidite chemistry (Inqaba, Pretoria, RSA) and 
prepared as described in Section 2.3.1. The tRNALys3 Mock sequences were cloned into 
the p901-1 vector as previously described (Section 2.3.2). Ligation mixtures were used to 
transform chemically competent E. coli (DH5-α cells). Transformed bacteria were plated 
onto LB agar plates containing ampicillin and incubated overnight at 37°C. Four clones 
were inoculated in 4 ml LB and incubated at 37°C overnight in a shaking incubator and the 
pDNA was purified from the bacterial cultures using a standard alkaline lysis plasmid 
isolation protocol (Appendix A.10). 
 
2.5 RNA Pol II-driven pri-miRNA-122 shuttles 
The method employed for the generation of RNA Pol II-driven pri-miRNA-122/5, -122/6 
and -122/10 has been previously described (15) and a description of the generation of pri-
miRNA-122/8 and -122/9 shuttles is given below. 
 
2.5.1  Construction of the pri-miRNA-122/8 and -122/9 shuttles 
Primer sets (Table 2.3) were designed for the generation first of pre-miRNA sequences by 
primer extension followed by PCR amplification of these templates with additional primer 
sets to create the complete pri-miRNA shuttle sequences (Figure 2.3). The 
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oligonucleotides were synthesised by standard phosphoramidite chemistry (IDT, IA, USA) 
and prepared as previously described (Section 2.1.1). The forward and reverse primers for 
the second round of PCR were designed to anneal to the pre-miRNA shuttles at the site of 
the stem sequence, subsequently completing the construction of the pri-miRNA shuttles. 
 
Primer extension was performed as a PCR in a final reaction volume of 25 µl containing 
100 pmol pre-miRNA forward primer; 100 pmol pre-miRNA reverse primer; 4 mM dNTP 
mix; 0.75 U GoTaq® Polymerase; 0.5 nM MgCl2 and was carried out in 1× GoTaq® Flexi 
Buffer using the GoTaq® Flexi DNA Polymerase Kit. The PCR thermal cycler was 
programmed to run with an initial denaturation at 94°C for 5 minutes, 24 cycles of standard 
PCR (denaturation at 94°C for 20 seconds; annealing at 57°C for 20 seconds and 
elongation at 72°C for 45 seconds) and a final elongation step at 72°C for 2 minutes and 
30 seconds. The amplified DNA fragments were subjected to agarose gel electrophoresis, 
excised and purified using the MinElute™ Gel Extraction Kit. The purified primer extended 
product was used as the DNA template for the subsequent PCR reaction, to generate the 
complete pri-miRNA shuttles. 
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Table 2.3: The forward and reverse primers for the initial primer extension reaction required for the construction of pri-
miRNA-122/8 and pri-miRNA-122/9 
 
 
miRNA Primer Sequence 
pre-miR-122/8 
F 
R 
5’GAGTTTCCTTAGCAGAGCTGCTCAAGGTCGGTCGTTGACATTGGTCTAAACATAAATGT 3’ 
5’GGATTGCCTAGCAGTAGCTACGAAAGGTCGTTCGTTGACATTTATGTTTAGACCAATGT 3’ 
pre-miR-122/9 
F 
R 
5’GAGTTTCCTTAGCAGAGCTGCAATTTATGCCTACAGCCTCCTAGTCTAAACAAAAGGAG 3’ 
5’GGATTGCCTAGCAGTAGCTACGGTTTATGCTTACAGCCTCCTTTTGTTTAGACTAGGAG 3’ 
pri-miR-122 
F 
R 
5’GACTGCTAGCTGGAGGTGAAGTTAACACCTTCGTGGCTACAGAGTTTCCTTAGCAGAGCTG 3’ 
5’GATCACTAGTAAAAAAGCAAACGATGCCAAGACATTTATCGAGGGAAGGATTGCCTAGCAGTAGCTA 3’ 
The complementary sequences of the pre-miRNA oligonucleotides for primer extension are underlined and in bold. The binding 
regions of pri-miRNA forward primer are underlined and are italicised for the reverse primer. (F) Forward; (R) Reverse. 
Assessing the efficacy of RNA Pol II- and RNA Pol III- promoter-driven effecter cassettes targeted to HBx 
 
32 
 
Figure 2.3: Construction of the pri-miRNA shuttles in pTZ57R/T.  
(A) The pre-miRNAs were generated by primer extension PCR. (B) The pre-miRNAs were 
amplified, generating the pri-miRNAs. (C) The pri-miRNA primer extension was ligated into the 
cloning vector pTZ57R/T. 
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The PCR components were prepared in a final reaction volume of 25 µl containing 100 ng 
primer extended product; 10 pmol universal pri-miRNA-122 forward primer; 10 pmol 
universal pri-miRNA-122 reverse primer; 10 mM dNTP mix; 0.75 U GoTaq® Polymerase; 
0.5 nM MgCl2 and was carried out in 1× GoTaq® Flexi Buffer using the GoTaq® Flexi 
DNA Polymerase Kit. The thermal cycler was programmed as described above and 
putative bands corresponding to the completed pri-miRNA shuttle sequences were 
identified using agarose gel electrophoresis, excised and purified using the MinElute™ 
Gel Extraction Kit. 
 
2.5.2  Cloning of the pri-miRNA-122 shuttles into pTZ57R/T 
The pri-miRNA-122 shuttle sequences were inserted into the InsT/Aclone™ PCR cloning 
vector pTZ57R/T. Ligation reactions were prepared in a final reaction volume of 20 µl 
containing 300 ng pri-miRNA-122/8 or -122/9 PCR product; 0.165 µg pTZ57R/T; 7.5 U T4 
DNA ligase and was carried out in 1× ligation buffer and ligated overnight at 16°C. The 
ligation mixtures were used to transform chemically competent E. coli (DH5-α cells). 
Transformed bacteria were plated onto LB agar plates containing ampicillin, X-gal and 
IPTG and incubated overnight at 37°C. Bacterial colonies containing the pTZ-pri-miRNA-
122 plasmids were identified using blue/white screening. Five clones of each miRNA-122 
shuttle were picked, inoculated in 4 ml LB and grown overnight in a shaking incubator. 
The pDNA was purified from the bacterial cultures using the High Pure Plasmid Isolation 
Kit.  
 
2.5.3  Orientation of the pri-miRNA shuttles in pTZ57R/T 
The orientation of the individual pri-miRNA shuttles inserted into the MCS of pTZ57R was 
determined by a double restriction digest with SpeI and NheI (Fermentas, MD, USA) in a 
final 20 µl reaction volume containing 5 U SpeI; 5 U NheI; 100 ng pTZ57R/miRNA-122/8 
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or -122/9 and was carried out in 1× Buffer Tango. The restriction digestions were 
incubated for one hour at 37°C. DNA fragments from the digested clones were subjected 
to agarose gel electrophoresis. Four pri-miRNA-122/8 clones and five pri-miRNA-122/9 
clones were prepared for automated cycle sequencing using the ABI Big Dye Terminator 
Cycle Sequencing Kit (Applied Biosystems, CA, USA) according to the manufacturer’s 
instructions (Appendix A.9.1). The chromatograms were analysed as previously described 
(Section 2.1.4). 
 
2.5.4  Cloning of the pri-miRNA shuttles into pCI-neo 
Sequences encoding the pri-miRNA shuttles were inserted into the mammalian 
expression vector pCI-neo (Promega, WI, USA) using directional cloning (Figure 2.4). The 
pCI-neo and the pTZ-pri-miRNA vectors were subjected to a double restriction digest with 
NheI and XbaI (Fermentas, MD, USA) in a final reaction volume of 30 µl containing 10 U 
NheI; 10 U XbaI; ~ 4000 ng pTZ-pri-miRNA or ~ 3000 ng pCI-neo and was carried out in 
1× Buffer Tango at 37°C for two hours. The NheI/XbaI digested pCI-neo backbone was 
dephosphorylated by CIP in a total reaction volume of 40 µl containing 10 U CIP and was 
carried out in 1× CIP buffer at 37°C for one hour. The digestion reaction was incubated at 
75°C in a dry heating block for ten minutes. The dephosphorylated pCI-neo backbone was 
subjected to agarose gel electrophoresis, the required bands excised and purified using 
the MinElute™ Gel Extraction Kit. The purity of the dephosphorylated pCI-neo vector DNA 
was verified using agarose gel electrophoresis. The DNA concentration (ng/µl) of 
dephosphorylated pCI-neo was measured at 260 nm.  
 
The dephosphorylated backbone and pri-miRNA shuttles were ligated in a final reaction 
volume of 20 µl containing ~1000 ng dephosphorylated pCI-neo; 3000 ng pri-miRNA 
shuttle fragment; 7.5 U T4 DNA ligase and was carried out in 1× ligation buffer at 16°C for 
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24 hours. Ligation mixtures were used to transform chemically competent E. coli (XL1-
Blue cells). Transformed bacteria were plated onto LB agar plates containing 100 µg/ml 
ampicillin and incubated overnight at 37°C. Colonies from each plate were picked, 
inoculated in 4 ml LB and incubated at 37°C overnight in a shaking incubator. The pCI-pri-
miR-122/8 and -122/9 DNA was purified from the bacterial cultures using a standard 
alkaline lysis plasmid isolation protocol (Appendix A.10). 
 
2.5.5  Confirmation of pri-miRNA inserts in pCI-neo 
The pCI-neo-miRNA-122/8 and -122/9 clones were subjected to a double restriction digest 
with NheI and HindIII (Fermentas, MD, USA) in a final reaction volume of 20 µl containing 
5 U NheI; 10 U HindIII; ~150 ng pCI-pri-miR-122/8 or -122/9 clones and was carried out in 
1× Buffer Tango at 37°C for one hour. Insertion of the pri-miRNA shuttles was verified 
using agarose gel electrophoresis. 
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Figure 2.4: Ligation of the pri-miRNA shuttle sequence into pCI-neo.  
pTZ-pri-miR-122/N and pCI-neo were digested separately with an NheI-XbaI double digest.  The 
pri-miR-122/N* fragment was ligated into the MCS of pCI-neo* at the analogous restriction sites. 
The complete pri-miRNA shuttle sequences were generated following transcription. 
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2.6  Target Vectors 
2.6.1  psiCHECK-HBx 
psiCHECK-HBx (51) is a 6806 bp dual luciferase reporter plasmid with the HBx ORF 
inserted downstream of the Renilla luciferase ORF (Promega, WI, USA). Renilla luciferase 
expression is driven by the SV40 promoter. Additionally the plasmid also contains the 
Firefly luciferase gene, which is driven by an HSV-TK promoter. Renilla luciferase activity 
is therefore an indication of HBx expression and Firefly luciferase activity is an indicator of 
transfection efficiency. The ratio of Renilla to Firefly luciferase is measured to assess the 
efficacy of RNAi effecters targeting the HBx sequence. 
 
2.6.2  pCH-9/3091 
The generation of pCH-9/3091 has been previously described (39). pCH-9/3091 contains a 
greater than genome length HBV sequence under the transcriptional control of the CMV 
immediate early promoter-enhancer. This structure functionally mimics the circular nature 
of the HBV genome by allowing a greater than genome length pregenomic RNA and 
subsequently cccDNA to be generated thereby simulating HBV replication. pCH-9/3091 is 
useful in observing the inhibition of HBV replication by RNAi effecters in vitro and in vivo. 
 
2.7  Cell Culture 
Human hepatoma cells (Huh7) were maintained in Dulbecco’s Modified Eagles Medium 
(DMEM) (BioWhittaker, MD, USA) supplemented with 10% foetal calf serum (FCS) 
(Invitrogen, CA, USA), penicillin (1000 U/ml), streptomycin (100 µg/ml) (Gibco BRL, United 
Kingdom) and ciprobay (100 µg/ml) (Highveld Biologicals, Johannesburg, RSA) in a 
humidified incubator at 37°C and 5% CO2.  
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2.8  Transfection of Huh7 cells for Dual Luciferase Assay and HBsAg 
Assay 
Prior to the day of transfection Huh7 cells were seeded at 40% confluency in Costar® 24-
well plates (Corning, NY, USA) in DMEM supplemented with 10% FCS, which was 
replaced on the day of transfection. Transfections were carried out on cells at a confluency 
of ~70% with Lipofectamine 2000™ (Invitrogen, CA, USA) according to the manufacturer’s 
instructions. Briefly, cells were transfected with 1 μg of total DNA constituted by combining 
90 ng of a target vector (psiCHECK-HBx or pCH-9/3091), 0.9 to 900 ng of an effecter 
vector (U6 shRNA, H1 shRNA, tRNALys3 shRNA or pri-miRNA-122 shuttle vectors), 10 ng 
of the green fluorescent protein (GFP) expression plasmid pCMV-GFP (44) and an empty 
vector (pTZ57R). The initial DNA concentrations (ng/µl) of the vectors were measured at 
260 nm and the vectors required for the transfection were prepared in quadruplicate at the 
correct amounts. The plasmids were transferred to sterile 1.5 ml microcentrifuge tubes and 
mixed before adding Opti-MEM (Gibco BRL, United Kingdom) to a final volume of 50 µl. 
The DNA/Opti-MEM mixtures were mixed and incubated at room temperature for five 
minutes. The volume of Lipofectamine 2000™ (Invitrogen, CA, USA) required for the 
transfection was aliquoted and mixed with the required volume of Opti-MEM and incubated 
at room temperature for five minutes. Fifty microlitres of the Lipofectamine 2000™/Opti-
MEM mix was added to 50 µl of the DNA/Opti-MEM mixes. The mixtures were incubated 
for 20 minutes at room temperature and 100 µl added per well in triplicate. The media was 
removed the following day and replaced with 500 µl of fresh DMEM supplemented with 
10% FCS, penicillin (1000 U/ml), streptomycin (100 µg/ml) and ciprobay (100 µg/ml). 
Forty-eight hours post transfection the cells were viewed using at 456 nm using a confocal 
fluorescence microscope (Zeiss Axiovision 100, Germany) and assessed for GFP 
expression. 
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2.8.1 Assessing RNAi effecter knockdown efficacy of HBV targets 
The ability of shRNAs and pri-miRNA shuttle sequences to inhibit the expression of target 
plasmid was assessed by transfecting Huh7 cells with 1 µg of total DNA with varying 
concentrations of RNAi effecter plasmid. Forty-eight hours post-transfection the cells were 
analysed for knockdown efficiency. Cells transfected with psiCHECK-HBx were analysed 
for luciferase activity using the Dual Luciferase Assay System (Promega, WI, USA) 
(Appendix A.11) and the Veritas™ Microplate Luminometer (Turner BioSystems, CA, 
USA). Growth medium from cells transfected with pCH-9/3091 was harvested and 
subjected to HBsAg ELISA using the MONOLISA® Ag HBs PLUS Kit (Bio-Rad, CA, USA) 
according to the manufacturer’s instructions (Appendix A.12). 
 
2.9  Transfection of Huh7 cells using Lipofectamine2000™ for total, 
nuclear and cytoplasmic RNA extraction  
Prior to the day of transfection Huh7 cells were seeded at 40% confluency to 10 cm plates 
(TPP®, Switzerland) in DMEM supplemented with 10% FCS, which was replaced on the 
day of transfection. Transfections were carried out on cells at a confluency of ~80% with 
Lipofectamine 2000™ according to the manufacturer’s instructions. Briefly, cells were 
transfected with 16 μg of total DNA constituted by 15 μg of either a Mock (pTZ57R) or an 
effecter vector (U6 shRNA, H1 shRNA, tRNALys3 shRNA or pri-miRNA-122 shuttle vectors) 
and 1 μg pCMV-GFP. The initial DNA concentrations (ng/µl) of the vectors were measured 
at 260 nm. The plasmids were aliquoted into sterile 1.5 ml microcentrifuge tubes and 
mixed before adding Opti-MEM to a final volume of 500 µl. The DNA/Opti-MEM solutions 
were mixed and incubated at room temperature for five minutes. The volume of 
Lipofectamine 2000™ required for the transfection was added to the required volume of 
Opti-MEM and incubated at room temperature for five minutes. Five hundred and fifteen 
microlitres of the Lipofectamine 2000™/Opti-MEM mix was added to 500 µl of the 
Assessing the efficacy of RNA Pol II- and RNA Pol III- promoter-driven effecter cassettes targeted to HBx 
 
40 
DNA/Opti-MEM mixes. The solutions were mixed by vortexing, incubated for 20 minutes at 
room temperature and 1000 µl added per plate. The media was removed the following day 
and replaced with 10 ml of fresh DMEM supplemented with 10% FCS, penicillin (1000 
U/ml), streptomycin (100 µg/ml) and ciprobay (100 µg/ml). Forty-eight hours post 
transfection the cells were viewed at 456 nm (Zeiss Axiovision 100, Germany) and 
assessed for GFP expression. 
  
2.10  Transfection of Huh7 cells using Calcium Chloride for total, nuclear 
and cytoplasmic RNA extraction 
Prior to the day of transfection Huh7 cells were seeded at 40% confluency into 10 cm 
plates (TPP®, Switzerland) in DMEM supplemented with 10% FCS, which was replaced 4 
hours prior to the transfection. Transfections were carried out on cells at a confluency of 
~80%. Briefly, cells were transfected with 16μg of total DNA constituted by combining 15 
μg of either a Mock (U6+1; H1 Mock; tRNALys3 Mock or pCI-neo) or an effecter vector (U6 
shRNA, H1 shRNA, tRNALys3 shRNA or pri-miRNA-122 shuttle vectors) and 1 μg pCMV-
GFP. The initial DNA concentrations (ng/µl) of the vectors were measured at 260 nm. Five 
hundred microlitres of nuclease free sterile water was aliquoted into a sterile 15 ml Falcon 
tube and the DNA was added. Five hundred microlitres of 2.5 M CaCl2 (Appendix A.13) 
was added to the water/DNA mix and the sample vortexed for 5 seconds. In a separate 
sterile 15 ml Falcon tube, 1 ml of 2× HEPES buffer (Appendix A.14) was added and the 
tube vortexed whilst the DNA/CaCl2 solution was added drop wise. The mixture was 
vortexed for 5 seconds to ensure thorough mixing before being incubated for 20 minutes at 
room temperature. One thousand microlitres was added drop wise to the cells whilst the 
plates were swirled continuously. The media was removed the following day and replaced 
with 10 ml of fresh DMEM supplemented with 10% FCS. Forty-eight hours post 
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transfection the cells were viewed at 456 nm (Zeiss Axiovision 100, Germany) and 
assessed for GFP expression. 
 
2.11 Total RNA Extraction for Northern Blot Hybridisation 
Forty-eight hours post transfection, the medium was removed and 1 ml of Tri® Reagent 
(Sigma, MO, USA) was added to the dish to lyse the cells. The lysate was pipetted several 
times and incubated at room temperature for five minutes before being transferred into a 
sterile 1.7 ml microcentrifuge tube. Two hundred microlitres of chloroform was added and 
the samples shaken vigorously for 15 seconds. The samples were incubated at room 
temperature for 2 minutes before being centrifuged at 12 000 × g for 15 minutes at 4°C. 
The aqueous phase containing the RNA ( 500 µl) was removed and transferred to a sterile 
1.7 ml microcentrifuge tube and mixed with 500 µl of isopropanol. The samples were 
stored overnight at -70°C. The following day, the samples were centrifuged at 12 000 × g 
for 30 minutes at 4°C to precipitate the RNA. The supernatant was removed and 500 µl of 
70% ethanol (v/v) added to the RNA pellet. The samples were centrifuged at 8 000 × g for 
5 minutes at 4°C. The supernatant was aspirated and the pellet was air-dried. The pellet 
was resuspended in 100 µl nuclease free water and the RNA stored at -70°C. 
 
2.12  Nuclear and Cytoplasmic Fractionation 
Three alternative methods (Appendix A.15; Appendix A.16 and Appendix A.17) were 
applied to fractionate transfected Huh7 cells before using the PARIS™ kit (Ambion, USA) 
according to the manufacturer’s instructions. Briefly, Huh7 cells were cultured and co-
transfected as described previously (Section 2.9 and Section 2.10). Forty-eight hours post 
transfection the medium was removed and the cells were washed three times with ice-cold 
saline-EDTA. The cells were trypsinised in 1 ml of 1× trypsin. Three milliliters of DMEM 
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was added to neutralise the trypsin. The cells were transferred to a sterile 15 ml Falcon 
tube and centrifuged at 120 × g for five minutes at 4°C. The supernatant was aspirated 
and the cells resuspended in one milliliter of ice cold saline and centrifuged at 120 × g for 
five minutes at 4°C. Cell pellets were gently resuspended in 300 µl ice-cold Cell 
Fractionation Buffer and incubated on ice for five minutes. The samples were centrifuged 
at 500 × g for 2 minutes at 4°C. The supernatant (cytoplasmic fraction) was aspirated and 
transferred into a sterile microcentrifuge tube and stored on ice. Three hundred microlitres 
ice cold Cell Fractionation Buffer was added to the pellet (nuclear fraction) before being 
centrifuged at 500 × g for one minute at 4°C. The supernatant was removed and 300 µl 
Cell Disruption Buffer was added to the pellet. The mixture was pipetted vigorously to lyse 
the nuclei. Initially, RNA was extracted from the lysates using the PARIS™ kit (Appendix 
A.18) however the yield was insufficient, thus the RNA was extracted from the nuclear and 
cytoplasmic fractions as described in Section 2.11.  
 
2.13 DAPI Staining of Nucleic Acids 
Ten microlitres of the nuclear and cytoplasmic lysates were pipetted onto the centre of 
clean microscopic slides. Five hundred microlitres of a gluteraldehyde (1% v/v) and 
formaldehyde (0.5% v/v) fixative was added to the nuclear fraction. A cover slip was 
placed over the mixture and the microscope slide incubated at room temperature for 20 
minutes. The slide was rinsed in 1× phosphate buffered saline (PBS) and blotted gently on 
paper towel. Three hundred microlitres of the DAPI stain (300 nM) (Molecular Probes, CA, 
USA) was aliquoted onto the centre of the slide. The slide was incubated at room 
temperature for five minutes, before being rinsed in 1× PBS and gently blotted on paper 
towel. A drop of mounting fluid was placed on the centre of the slide and a clean cover slip 
gently lowered on top. The slide was incubated at room temperature for 24 hours to allow 
the mounting solution to solidify. The nuclear fractions were viewed using confocal 
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fluorescence microscopy at 365 nm (Zeiss Axiovision 100, Germany) and the stained 
nuclei were identified by their blue fluorescence.  
 
2.14 Northern Blot Hybridisation 
Thirty micrograms of RNA extracted from transfected cells was subjected to 
polyacrylamide gel electrophoresis (PAGE) on a 15% polyacrylamide gel (Appendix A.19). 
The RNA was transferred to a piece of positively charged nylon membrane (Hybond-N+, 
GE Healthcare, NJ, USA) that had been cut to the size of the gel. Thereafter the RNA on 
the membranes was cross-linked using ultraviolet (UV) radiation at 200 J/cm2 followed by 
incubation at 80°C for one hour. The membrane was pre-hybridised in 10 ml of Rapid-
hyb™ Buffer (GE Healthcare, NJ, USA) at 42°C for 20 minutes. An oligonucleotide probe 
against the guide strand of the processed shRNA 5 and pri-miRNA-122/5 (Table 2.4) was 
synthesised using standard phosphromadite chemistry (Inqaba, Pretoria, RSA). 
Lyophilised oligonucleotides were resuspended to 100 µM and working stocks of 10 µM 
prepared. The probe was radioactively labelled using 32P (Appendix A.20), added to the 
membrane and incubated overnight in a rotating oven at 42°C. The membrane was 
subjected to an initial low stringency wash at 25°C for 20 minutes with 5× SSC (Appendix 
A.21) and 0.1% (w/v) sodium dodecyl sulphate (SDS). Thereafter, the membrane was 
washed twice at 42°C for 15 minutes (1× SSC; 0.1% SDS) and subjected to either 
autoradiography or phosphor imaging using the FLA-7000 (Fujifilm, Tokyo, Japan). The 
membrane was stripped (1% SDS) at 80°C for 30 minutes and probed for either U6 
snRNA or tRNA (Table 2.4). 
 
 
 
 
Assessing the efficacy of RNA Pol II- and RNA Pol III- promoter-driven effecter cassettes targeted to HBx 
 
44 
Table 2.4: Sequences of probes used in Northern Blot Hybridisation 
 
 
2.15  In vivo Analysis of Effecter Sequences Targeted to HBx 
Eight groups of five mice each were hydrodynamically injected via the tail vein. Injection 
solutions were prepared containing 5 µg of the target vector pCH-9/3091, 5 µg of an 
effecter vector (U6 shRNA 5, H1 shRNA 5, tRNALys3 shRNA 5 or pri-miRNA-122/5 shuttle) 
or Mock (U6 +1, H1 Mock, tRNALys3 Mock or pCI-neo) and 5 µg of psiCHECK-2.2. A 
volume of saline (containing the DNA) equivalent to 10% of the mouse’s body weight was 
injected into the tail vein over a short period of time (approximately 10 seconds). The mice 
were bled retro-orbitally on day three and day five post injection. The mice were sacrificed 
on day five and the livers harvested for further analysis. All experiments carried out on 
mice were in accordance with protocols approved by the University of the Witwatersrand 
Animal Ethics Screening Committee (Appendix B). 
 
2.15.1 HBsAg Assay using ELISA 
Twenty five microlitres of serum was diluted with seventy five microlitres of normal saline 
and subjected to HBsAg ELISA using the MONOLISA® Ag HBs PLUS Kit (Bio-Rad, CA, 
USA) according to the manufacturer’s instructions (Appendix A.12).  
 
 
Probe Sequence 
shRNA 5 5’CCGTGTGCACTTCGCTTC 3’ 
U6 snRNA 5’TAGTATATGTGCTGCCGAAGCGAGCA 3’ 
tRNA 5’GGACCCTCAGATTAAAAGTCTGATGCTC 3’ 
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2.15.2 Nucleic Acid Isolation of HBV DNA from Mouse Serum 
Total nucleic acids were isolated from mouse serum using the MagNA Pure LC Total 
Nucleic Acid Isolation Kit (Roche, Germany) and the MagNA Pure Instrument (Roche, 
Germany) according to the manufacturer’s instructions. 
 
2.15.3 Extraction of Genomic DNA (gDNA) from Homogenised Liver 
The harvested mouse livers were weighed and an equal volume of phosphate buffered 
saline (PBS) added. The livers were homogenised using a CAT X120 homogeniser at 30 
000 rpm. Briefly, 100 mg of homogenised mouse liver was transferred into a sterile 15 ml 
Falcon tube and 1.2 ml digestion buffer (100 mM NaCl; 10 mM Tris-Cl pH 8.0; 25 mM 
EDTA pH 8.0; 0.5% SDS and 0,1 mg/ml Proteinase K) was added. The samples were 
incubated for 18 hours in a shaking water bath at 50°C. An equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the digested liver solution. The 
tubes were gently agitated to ensure thorough mixing and centrifuged at 1700 × g for ten 
minutes at 4°C. One millilitre of the aqueous layer containing the genomic DNA (gDNA) 
was aspirated and transferred into a sterile 15 ml Falcon tube. Five hundred microlitres of 
ammonium acetate (7.5 M) was added and the tubes gently agitated. Two milliliters of 
absolute ethanol was added and the samples were stored overnight at -20°C. The 
following day the samples were centrifuged at 1700 × g for two minutes at 4°C to pellet the 
gDNA. The supernatant was aspirated and 1 ml of 70% ethanol (v/v) was added to the 
gDNA pellet. The samples were centrifuged at 1700 × g for two minutes at 4°C. The 
supernatant was aspirated and the pellet air-dried. The pellet was resuspended in 100 µl 
nuclease free water and stored at -20°C. The concentration of the gDNA was determined 
by measuring optical absorbance at 260 nm and working stocks of 100 ng/µl prepared. 
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2.15.4 Quantitative Real-time PCR (qRT-PCR) for the detection of rcDNA and 
cccDNA 
The total amounts of circulating viral particles in the serum and liver were assessed by 
real-time quantitative PCR (qPCR) using the LightCycler® FastStart DNA MasterPLUS 
SYBR Green I kit (Roche, Germany) according to the manufacturer’s instructions 
(Appendix A.22). Total amounts of HBV DNA, cccDNA and rcDNA within the harvested 
livers were measured using an in house assay (2). Total HBV was measured using the 
HBV rc/cccDNA primer sets which amplify the preS1 region and cccDNA was detected 
using the cccDNA primer sets which were designed to flank the direct repeats (Table 2.5). 
Efficacy of DNA delivery to the liver was detected by the Rluc primer sets (Table 2.5), 
which amplify the Renilla luciferase sequence of psiCHECK 2.2. 
 
Table 2.5: Primer sets used in real-time quantitative PCR 
 
 
Quantification Primer Sequence 
HBV rc-DNA 
F 
R 
5’TTATTATCCAGAACATGTAGTTAATCATTACTTCC3’ 
5’TTGATGGGATTGAAGTCCCAATCTGGATT 3’ 
HBV ccc-DNA 
F 
R 
5’TTCTCATCTGCCGGTCCGTGT 3’ 
5’TGGGACATGTACAAGAGATGATTAGGC 3’ 
Rluc 
F 
R 
5’AAATCATCTTTGTGGGCCACGACTGG 3’ 
5’GAACTCCTCAGGCTCCAGTTTCCGCAT3’ 
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2.16  Statistical Analysis 
All data was analysed using the software package GraphPad Prism® version 4.0 
(GraphPad Software Inc.). All in vitro data were expressed as the mean ± the normalised 
standard deviation of the mean and the statistical differences of triplicate data determined 
using the two-tailed unpaired student t-test with a confidence interval (CI) of 95%.  
 
In vivo HBsAg data were expressed as the mean ± the standard deviation of the mean and 
the statistical differences of data determined using the two-tailed unpaired student t-test 
with a confidence interval (CI) of 95%.  
 
In vivo qPCR serum data were expressed as the mean ± the normalised standard 
deviation of the mean and the statistical differences of data determined using the two-
tailed unpaired student t-test with a confidence interval (CI) of 95%.  
 
In vivo qPCR liver data expressed as the mean ± the normalised standard deviation of the 
mean and the statistical differences of triplicate data determined using the two-tailed 
unpaired student t-test with a confidence interval (CI) of 95%. 
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3  RESULTS 
3.1 Design and Generation of H1 shRNA expression cassettes 
The H1 shRNA expression cassettes were designed to contain the anti-HBV effecter 
sequences as described by Carmona et al (5). The shRNAs comprised a 25 base pair (bp) 
anti-guide strand, a 10 bp loop, a 25 bp guide strand, which was homologous to the HBx 
target and a 6 bp termination site (Figure 3.1). The complete H1 shRNA expression 
cassettes were verified to be 317 nucleotides (Appendix C.1). The sequences of the H1 
shRNA expression cassettes were assessed and hairpin structures found to have a 100% 
homology to the predicted structures (Appendix C.2 to C5). A G A base change was 
identified in the H1 promoter region at  152 nt for all shRNA expression cassettes, 
however this had no influence on the transcriptional activity of the H1 promoter as 
demonstrated by the data observed in the investigation. 
 
 
 
Figure 3.1: H1 shRNA expression cassette structure.  
Driven by the RNA Pol III promoter H1, the shRNA expression cassettes were designed to be 66 
nucleotides in length. The 25 bp anti-guide strand contained four G-U or C-A mismatches (black). 
The 10 bp loop was identical for all the shRNA expression cassettes. The 25 bp guide strand was 
complementary to the HBx target. (Diagram not to scale).  
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3.2 Design and Generation of the tRNALys3 shRNA expression 
cassettes 
The tRNALys3 shRNA expression cassettes were comprised of a 21 bp anti-guide strand, a 
9 bp loop, a 21 bp guide strand and a 6 bp termination site (Figure 3.2). The guide and 
anti-guide were designed to contain the anti-HBV sequences as described by Carmona et 
al (5).The shRNAs sequences were shortened by four nucleotides at the 3’ and 5’ end 
respectively. The 9 bp loop (5’ TTT GTG TAG 3’) was common to tRNALys3 shRNA 5, 
shRNA 6 and shRNA 8. The five nucleotides preceding the loop structure of tRNALys3 
shRNA 9 and shRNA 10 (TTTTT) could cause early transcriptional termination (Appendix 
C.6). A single T A nucleotide change in the first position of the loop (5’ ATT GTG TAG 3’) 
was incorporated as a preventative measure against early transcriptional termination. The 
sequences of the tRNALys3 shRNA expression cassettes were assessed and the hairpin 
structures found to have 100% homology to the predicted structures (Appendix C.6 to 
C.11). A single base change (T136A) was observed within the tRNALys3 promoter. The 
efficacy of the investigation demonstrated that this base change had no effect on the 
transcriptional capabilities of the promoter.  
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Figure 3.2: Schematic representation of the tRNA
Lys3 
shRNA expression cassettes.  
The shRNA expression cassettes were designed with 21 bp anti-guide and guide strand. The anti-
guide contained 4 G-U or C-A mismatches. The 9 bp loop was altered slightly for shRNA 9 and 
shRNA 10. The tRNA
Lys3
 promoter starts transcription within the promoter structure, thus the shRNA 
expression cassette will be transcribed onto the 3’ GGCG acceptor arm. (Diagram not to scale). 
 
3.3 Design and Generation of pri-miRNA-122/8 and pri-miRNA-122/9 
shuttles 
The pri-miRNA-122/8 and pri-miRNA-122/9 shuttles were designed as described by Ely et 
al (15). The natural guide and complementary strand of pre-miRNA-122 wild type (wt) 
were replaced with the anti-HBV anti-guide and guide sequence of shRNA 8 and shRNA 9 
as previously described designed (5) (Figure 3.3). The design of the pri-miRNA shuttles 
was assessed using the M-fold secondary folding structure programme. No significant 
difference was observed between the folding of the pri-miRNA-122/8 and pri-miRNA-122/9 
shuttles when compared to the pri-miRNA-122/wt (Figure 3.4). 
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Figure 3.3: Design of pri-miRNA-122/8 and pri-miRNA-122/9 shuttles.  
The pri-miRNA shuttles were designed to be structurally identical to the pri-miRNA-122/wt. The pre-miRNA-122/wt guide and anti-guide sequences 
were replaced with the guide sequence (purple) complementary to the HBx target. The anti-guide sequence (blue) and guide sequence indicate 
the processed pre-miRNA construct. Figure adapted from Ely et al (15). 
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Figure 3.4: M-fold predictions of pri-miRNA-122/8 and pri-miRNA-122/9 shuttles.  
There were no observed differences in the predicted secondary structure folding of the pri-miRNA-
122/8 and pri-miRNA-122/9 effecter sequences when compared to pri-miRNA-122/wt. The ΔG 
values for pri-miRNA-122/8 and pri-miRNA-122/9 were ΔG=-47.6 and ΔG=-48.7 respectively. 
These values correspond to the pri-miRNA-122/wt (ΔG=-45.9) illustrating structural similarity of 
secondary folding. 
 
 
 
 
 
Pri-miRNA-122/wt Pri-miRNA-122/8 Pri-miRNA-122/9 
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3.4 GFP expression as a indicator of transfection efficacy 
To assess the efficacy of DNA delivery, Huh7 cells were transfected with a eGFP-
expressing plasmid and analysed for expression of the reporter gene. Figure 3.5 illustrates 
the consistency of expressed GFP confirming transfection efficacy and consistent delivery 
of DNA between Mock and U6 shRNA transfected cells. Consistent expression of GFP 
was observed over all in vitro transfections. 
 
 
 
Figure 3.5: A representation of GFP expression in Huh7 cells as a measure of transfection 
efficacy.  
Huh7 cells were co-transfected with RNA Pol III- or Pol-II expression cassettes at varying target to 
effecter ratios or a comparative Mock and the GFP expression vector pCMV-GFP. The morphology 
of the cells was assessed under transmitted light and the efficacy of GFP expression at 456 nm. 
The efficacy of transfection and delivery of DNA were consistent for these Huh7 cells transfected 
with U6 shRNA 9. 
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3.5.  The efficacy of RNA Pol III and RNA Pol II transcribed effecter 
sequences to target HBx for knockdown 
Previously, a panel of ten U6 shRNA expression cassettes was constructed to target 
highly conserved sites within the HBx sequence (5). Primary findings established four 
shRNA expression cassettes, which were particularly efficacious in targeting and inhibiting 
replicating HBV. U6 shRNA 5 and U6 shRNA 6 caused knockdown of between 80 and 
95% in comparison to Mock treated cells, whilst U6 shRNA 8 and U6 shRNA 9 caused 
knockdown of between 80 – 85%. A fifth shRNA expression cassette, U6 shRNA 10, failed 
to knockdown the target. These five shRNAs were selected to investigate whether two 
different RNA Pol III promoters, H1 and tRNALys3, could actively transcribe these shRNAs 
and target HBV as effectively as the U6 promoter-driven shRNAs. 
 
To assess whether the H1 and tRNALys3 shRNA expression cassettes were capable of HBx 
target knockdown, a co-transfection assay was performed. Huh7 cells were transfected 
with the shRNA expression cassettes and the target vector psiCHECK HBx at an effecter 
to target ratio of 10:1. The efficacy of the effecter sequences to knockdown the HBx target 
was measured by comparing the ratio of Renilla to Firefly luciferase activity. In comparison 
to Mock treated cells, H1 shRNA 5 caused knockdown of  92% whilst tRNALys3 shRNA 5 
caused knockdown of  90%. H1 shRNA 10 and tRNALys3 shRNA 10 failed to knockdown 
the HBx target (data not shown). These data correlate with previous findings (5). 
 
After establishing the RNA Pol III promoter-driven shRNA expression cassettes were 
capable of knocking down the HBx target, it was decided to compare the efficacies of 
these three different RNA Pol III promoter-driven shRNA expression cassettes to an RNA 
Pol II promoter-driven pri-miRNA shuttle. Five target to effecter ratios were chosen 
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(1:0.0025; 1:0.01; 1:0.05; 1:0.1 and 1:10) and the efficacy of HBx target knockdown 
assessed. All data were normalised to a comparative mock (n=3).  
 
3.5.1 Effective HBx target knockdown by Pol II- and Pol III-driven effecter 
sequences 5 and 6  
The shRNA 5 expression cassettes revealed a trend in knockdown with the most effective 
knockdown achieved at the highest RNAi effecter to target plasmid ratios (Figure 3.6). The 
U6, H1 and tRNALys3 shRNA 5 expression cassettes caused knockdown of between 88% - 
90% at a ratio of 1:10 and 80 - 88% at a ratio of 1:0.1, which was significantly different 
when compared to Mock transfected cells (p<0.05). Furthermore, significant target 
knockdown was observed at 1:0.05, 1:0.01 and 1:0.0025 (Appendix C.1). Taken together, 
these data indicate that even following a decrease of 100 fold in effecter ratio (1:10 to 
1:0.1) the expressed effecter sequences are capable of substantial knockdown, and at a 
decrease of 200 fold (1:10 to 1:0.05), target knockdown is still greater than 60%. 
 
At 1:10, pri-miRNA-122/5 caused significant target knockdown of 88%, which decreased 
two-fold at 1:0.1 (Figure 3.6). Pri-miRNA-122/5 was incapable of significant knockdown at 
decreased effecter ratios (Appendix C.1). These data suggest the efficacy of the RNA Pol 
III shRNA 5 expression cassettes to target HBx is greater than the RNA Pol II pri-miRNA 
shuttle.  
 
U6 shRNA 6 and H1 shRNA 6 showed a similar trend in knockdown to that observed for 
the RNA Pol III-promoter driven shRNA expression cassettes (Figure 3.6). U6 shRNA 6 
and H1 shRNA 6 caused knockdown of 90% at a ratio of 1:10 and between 85% - 90% at 
1:0.1, which was significantly different when compared to Mock transfected cells (p<0.05). 
Furthermore, significant knockdown was observed for U6 shRNA 6 and H1 shRNA 6 at 
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1:0.05, 1:0.01 and at 1:0.0025 for U6 shRNA 6 (Figure 3.7). Taken together these data 
indicate a correlation in knockdown to U6 shRNA 5 and H1 shRNA 5. 
 
The efficacy of target knockdown by tRNALys3 shRNA 6 and pri-miRNA-122/6 was 
substantially reduced in comparison to U6 and H1 shRNA 6. In comparison to Mock 
transfected cells, tRNALys3 shRNA 6 and pri-miRNA-122/6 were capable of significantly 
knocking down the HBx target by 60% at 1:10 (p>0.05). At 1:0.01, target knockdown was 
no longer significant for tRNALys3 shRNA 6 and pri-miRNA-122/6 (Figure 3.7) (Appendix 
C.2). 
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Figure 3. 6: HBx knockdown by Pol III-shRNA 5 and miRNA-122/5.  
(A) Schematic representation of the psiCHECK HBx vector, indicating the target site of the effecter sequence (purple). (B) Knockdown of HBx was 
assessed using the dual luciferase assay. Cultured cells were co-transfected with a psiCHECK HBx target plasmid and either a RNA Pol II driven 
pri-miRNA-122/5 shuttle or Pol III-driven shRNA 5. Knockdown was normalised to the respective Mocks for comparison. Error bars indicate the 
normalised standard error of the mean (n=3). The p values are discussed within the text. *p<0.05. 
  
58 
 
Figure 3.7: HBx knockdown by Pol III-shRNA 6 and miRNA-122/6.  
(A) Schematic representation of the psiCHECK HBx vector, indicating the target site of the effecter sequence (blue). (B) Knockdown of HBx was 
assessed using the dual luciferase assay. Cultured cells were co-transfected with a psiCHECK HBx target plasmid and either a RNA Pol II driven 
pri-miRNA-122/6 shuttle or a Pol III-driven shRNA 6. Knockdown was normalised to the respective Mocks for comparison. Error bars indicate the 
normalised standard error of the mean (n=3). The p values are discussed within the text. *p<0.05.  
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3.5.2 Decreased HBx target knockdown by Pol II- and Pol III-driven effecter 
sequences 8, 9 and 10 
The trend of knockdown previously observed for U6 was maintained by U6 shRNA 8. At an 
effecter to target ratio of 1:10, U6 shRNA 8 caused significant target knockdown of 85% 
in comparison to Mock treated cells (p<0.05). At 1:0.1, target knockdown of 65% was 
achieved, and the knockdown was no longer significant at 1:0.0025. H1 shRNA 8 followed 
a similar trend to U6 shRNA 8 (Appendix C.3). Although target knockdown of 62% was 
significant at 1:10, and at 1:0.1 and 1:0.05 (p<0.05), the efficacy of knockdown at 1:0.1 
and 1:0.05 was low at, 20% and 40% respectively (Figure 3.8). Although the knockdown 
efficacy of tRNALys3 shRNA 8 and pri-miRNA-122/8 was considered significant at 1:10 and 
1:0.1 (p<0.05), the percentage of knockdown failed to exceed 48%. Pri-miRNA-122/8 was 
slightly more efficacious with significant knockdown at 1:0.05, 1:0.01 and 1:0.0025. Taken 
together, these data indicate the effecter sequence is only capable of >80% knockdown 
when under the expression of the potent promoter, U6. 
 
Figure 3.6 and Figure 3.7 indicate significant target knockdown primarily by the RNA Pol III 
promoters, U6 and H1. The trend of HBx target knockdown by U6 shRNA 9 and H1 
shRNA 9 followed this established trend. At 1:10 target knockdown by U6 shRNA 9 and 
H1 shRNA 9 was significant, at  80-85% in comparison to Mock treated cells (p<0.05). U6 
and H1 shRNA 9 caused significant knockdown at 1:0.1, 1:0.05 and 1:0.01 (Figure 3.9). It 
was only at the lowest effecter 1:0.0025 at which knockdown was not significant (Appendix 
C.4). At an effecter ratio of 1:10, tRNALys3 shRNA 9 and pri-miRNA-122/9 caused 
significant knockdown (p<0.05) of 77% and 68% respectively. As the effecter 
concentration decreased to 1:0.01, target knockdown was decreased to  22% and 38%, 
which was analysed to be significantly different. Further decrease in effecter concentration 
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indicated limited knockdown by tRNA Lys3 shRNA 9 and pri-miRNA-122/9 was not 
significant. 
 
RNA Pol III-promoter driven shRNA 10 expression cassettes and RNA Pol II-promoter 
driven pri-miRNA-122/10 shuttle indicated no significant knockdown (Figure 3.10) 
(Appendix C.5). These data correlate with previous findings (5).1 
 
 
 
 
                                                          
1 The complete statistical analyses can be found in Appendix Table C.1 to C.5 
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Figure 3.8: HBx knockdown by Pol III-shRNA 8 and miRNA-122/8.  
(A) Schematic representation of the psiCHECK HBx vector, indicating the target site of the effecter sequence (green). (B) Knockdown of HBx was 
assessed using the dual luciferase assay. Cultured cells were co-transfected with a psiCHECK HBx target plasmid and either a RNA Pol II driven 
pri-miRNA-122/8 shuttle or a Pol III-driven shRNA 8. Knockdown was normalised to the individual Mocks for comparison. Error bars indicate the 
normalised standard error of the mean (n=3). The p-values are discussed within the text. *p<0.05. 
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Figure 3.9: HBx knockdown by Pol III-shRNA 9 and miRNA-122/9.  
(A) Schematic representation of the psiCHECK HBx vector, indicating the target site of the effecter sequence (pink). (B) Knockdown of HBx was 
assessed using the dual luciferase assay. Cultured cells were co-transfected with a psiCHECK HBx target plasmid and either a RNA Pol II driven 
pri-miRNA-122/9 shuttle or a Pol III-driven shRNA 9. Knockdown was normalised to the individual Mocks for comparison. Error bars indicate the 
normalised standard error of the mean (n=3). The p-values are discussed within the text. *p<0.05. 
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Figure 3.10: HBx knockdown by Pol III-shRNA10 and miRNA-122/10.  
(A) Schematic representation of the psiCHECK HBx vector, indicating the target site of the effecter sequence (orange). (B) Knockdown of HBx was 
assessed using the dual luciferase assay. Cultured cells were co-transfected with a psiCHECK HBx target plasmid and either a RNA Pol II driven 
pri-miRNA-122/10 shuttle or a Pol III-driven shRNA 10. Knockdown was normalised to the individual Mocks for comparison. Error bars indicate the 
normalised standard error of the mean (n=3). The p-values are discussed within the text. 
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3.6. Effective inhibition of HBsAg secretion from cultured cells after 
transfection with by anti-HBV expression cassettes 
After establishing that the shRNA expression cassettes and pri-miRNA shuttles effectively 
knocked down the expressed HBx target, the efficacy at which these effecter sequences 
could inhibit actively replicating virus was assessed. The target vector pCH-9/3091 was 
co-transfected with the shRNA expression cassettes, pri-miRNA shuttles and a 
comparative mock. The concentration of HBsAg secreted within the media of transfected 
cells was measured and the efficacy of inhibition determined. All data were normalised to a 
comparative mock (n=3). 
 
The U6 promoter-driven shRNA 5, 6, 8 and 9 expression cassettes significantly inhibited 
HBsAg secretion by 60% in comparison to the Mock treated cells (p<0.05) (Figure 3.11). 
Furthermore, a significant inhibition of HBsAg secretion was caused by H1 and tRNALys3 
shRNA 5, 6 and 9; and pri-miRNA-122/5 -/6 and -/9. (Figure 3.11 and Figure 3.12), 
however there was no significant inhibition (p>0.05) caused by H1 and tRNALys3 shRNA 8 
and pri-miRNA-122/8 (Appendix C.6). Taken together these data correlate with the 
findings in Section 3.5. A 2.5 fold increase in HBsAg was observed for U6 shRNA 10. In 
addition, H1 shRNA 10 and pri-miRNA-122/10 caused increases in HBsAg concentrations, 
which were significantly different to the Mock treated cells (p<0.05). This phenomenon has 
been observed in previous investigations, however a suitable explanation has not yet been 
established. 
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Taken together, the trend of HBsAg inhibition and targeted HBx knockdown identify the 
effecter sequences 5 and 6 as the most efficacious at targeting HBV, whilst U6 and 
tRNALys3 were established to be the most effective promoters2.   
                                                          
2 The complete statistical analyses can be found in Appendix Table C.6 
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Figure 3.11: Inhibition of HBsAg by U6 and H1 promoter-driven shRNA expression cassettes.  
(A) Schematic representation indicating the sites targeted by the different effecter sequences. (B) The target vector pCH-9/3091 was co-
transfected with the shRNA expression cassettes and a mock for comparison. Error bars indicate the normalised standard error of the mean (n=3). 
*p<0.05. 
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Figure 3.12: Inhibition of HBsAg by tRNA
Lys3
 and CMV promoter-driven shRNA expression cassettes.  
(A) Schematic representation indicating the sites targeted by the different effecter sequences. (B) The target vector pCH-9/3091 was co-
transfected with the shRNA expression cassettes and a mock for comparison. Error bars indicate the normalised standard error of the mean (n=3). 
*p<0.05. 
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3.7  Pol III- and Pol II- expression cassettes do not saturate the RNAi 
pathway. 
The introduction of exogenous RNAi effecter sequences have been known to cause toxic 
effects including off-target silencing and saturation of the endogenous RNAi pathway. To 
assess potential saturation of the endogenous miRNA pathway by exogenous RNAi 
effecter sequences disruption of miR-16 silencing of a luciferase target was assessed. The 
shRNA 5 and shRNA 6 expression sequences and the pri-miRNA-122/5 and -122/6 
shuttles were selected to challenge miR-16 functionality, as these effecter sequences 
caused the greatest knockdown of the HBx target. As a positive control for disruption of 
miR-16 functionality a miR-16 sponge expression cassette (pTZ-U6-miR-16S×7) (14) was 
included. Neither of the effecter sequences was found to disrupt miR-16 target silencing 
(p<0.05), whereas the sponge sequence significantly derepressed target expression 
(Figure 3.13). This is a clear indication that the effecter sequences do not saturate the 
endogenous RNAi pathway3.  
 
 
 
 
 
 
 
 
 
                                                          
3 The complete statistical analyses can be found in Appendix Table C.7 
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Figure 3.13: Saturation assay of miR-16.  
To assess disruption of the endogenous miRNA pathway, cultured cells were co-transfected with a miR-16 luciferase target plasmid and various 
RNA Pol II- and Pol III-driven expression cassettes. pTZ-U6-miR-16S×7 sponge is a positive control for disruption of miR-16 silencing activity. All 
data were carried out in triplicate and normalised to the Mock. Bars indicate normalised standard error of the mean (n=3). The p values discussed 
within the text. *p<0.05 
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3.8 DAPI Stain 
To assess whether the fractionation of the nuclear and cytoplasmic components were 
effective and if contamination had occurred between the fractions, the lysates were stained 
with DAPI and assessed for the presence of nucleic acids within the nuclei. The nuclear 
lysates obtained from Method 1 (19), Method 3 (4) and the PARIS™ kit was compared. 
The fractionated lysates from the PARIS™ kit indicate minimal amounts of nucleic acids 
within the cytoplasmic fraction, when compared to the nuclear fraction (Figure 3.14). 
Taken together this data indicates a slight contamination of the nuclear fraction within the 
cytoplasmic fraction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Presence of nucleic acids within fractionated lysates at 10 x Magnification.  
Nulceic acids were depicted within the nuclear lysates, with minimal amounts in the cytoplasmic 
fraction for the PARIS™ kit 
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3.9 Expression and processing of anti-HBV effecter sequences in total, 
nuclear and cytoplasmic fractions 
Northern blot hybridisation was used to detect the Dicer processed anti-HBV effecter 
sequence from the different shRNA 5 expression cassettes and pri-miRNA-122/5 shuttle in 
total, nuclear and cytoplasmic RNA extracts.  
 
3.9.1 Processed anti-HBV guide strands detected in Total RNA  
Hybridisation to a radiolabelled probe complementary to the processed guide sequence 5 
detected a band at 21 nucleotides for U6, H1 and tRNALys3 shRNA 5 (Figure 3.15) 
indicating processed mature guide strand. The processed guide strands for U6, H1 and 
tRNALys3 were detected after 24 hours exposure, however the miRNA-122/5 remained 
undetected, even when exposed for 5 days. Large amounts of U6 and H1 precursors were 
detected at  65 nt. tRNALys3 precursors were detected at > 100 nt and at 55 nt which 
conform to the expected sizes of unprocessed pre-tRNALys3 shRNA 5 and unprocessed 
tRNALys3 shRNA 5. The amount of U6 and H1 precursors in comparison to H1 and 
tRNALys3 indicates a high level of expression for U6 and decreased expression, which is in 
accordance with published literature. Hybridisation of a radiolabelled probe complementary 
to U6 snRNA confirmed equal loading of the RNA samples.  
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Figure 3.15: Northern blot hybridisation of processed anti-HBV effecter sequences of a total 
RNA lysate.  
Total RNA was extracted from Huh7 cells that ad been transfected with the U6, H1 or tRNA
Lys3
 
shRNA 5, pri-miRNA-122/5 or Mock (pCI-neo) plasmids. Signals were detected following the 
hybridisation of a radioalabelled probe to the processed anti-HBV guide 5. The processed guide 
strand was detected at 21 nucleotides. Precursors of the processed product were detected for U6 
and H1 (purple arrow) and tRNA
Lys3
 (green arrow). Processed miRNA-122/5 was not detected. The 
blot was stripped and reprobed with U6 snRNA to confirm equal loading of RNA.  
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3.9.2 Processed anti-HBV guide strands detected in Total and Cytoplasmic 
RNA 
To assess in which compartment of the cell the majority of the mature guide strand 
occurred, Lipofectamine2000™ transfected Huh7 cells were fractionated into nuclear and 
cytoplasmic lysates (Method 1) and the RNA extracted. The overall yield of nuclear RNA 
was  20 ng, thus the fraction was excluded. Twenty-four hours post exposure the 
processed guide strand was detected as a band at 21 nucleotides for U6, H1 and 
tRNALys3 shRNA 5, in the total and cytoplasmic fractions. The guide strand processed from 
miRNA-122/5 remained undetected, even at 5 days exposure (Figure 3.16). Precursors 
were detected for U6, H1 and tRNALys3. Hybridisation of a radiolabelled probe 
complementary to U6 snRNA was used to confirm equal loading of the RNA samples and 
to detect nuclear RNA. High levels of nuclear RNA were detected in the cytoplasmic 
fraction, suggesting lysis of the nuclei prior to the separation of the fractions. Hybridisation 
of a radiolabelled probe complementary to tRNA detected high levels within the 
cytoplasmic fraction. The tRNA occurring in the cytoplasmic fraction was detected at 
higher levels than the previously detected nuclear RNA and the levels of tRNA within the 
cytoplasmic fraction are comparable and almost identical to the levels detected in the total 
lysate. Taken together, these data suggest the majority of the RNA is concentrated in the 
cytoplasmic fraction however the nuclear fraction is required to corroborate this finding.  
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Figure 3.16: Northern blot hybridisation of the processed anti-HBV effecter sequence (guide 
5) within total lysate and cytoplasmic RNA fraction.  
Hybridisation of a radiolabelled probe detected the processed anti-HBV guide 5 at 21 nt for U6, H1 
and tRNA
Lys3
 shRNA 5. Precursors of U6 and H1 (purple arrow) and tRNA
Lys3
 (green arrow) were 
detected. Processed miRNA-122/5 was not detected. The blot was stripped and reprobed for U6 
snRNA, to confirm equal loading of the RNA samples and to detect nuclear RNA in the cytoplasmic 
fraction. The blot was stripped again and reprobed for tRNA. 
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3.9.3 Detection of processed anti-HBV guide strands in total, nuclear and 
cytoplasmic RNA 
Three different methods for fractionating the nucleus and cytoplasm were attempted to 
obtain suitable RNA concentrations from the respective fractions. The overall yields of 
extracted nuclear RNA seldom exceeded 200 ng in 106 cells and in the cases where a 
suitable concentration was obtained, the RNA was severely degraded (Appendix C.12 and 
C.13). Combining the most efficient method of fractionation and RNA extraction, the 
nuclear and cytoplasmic fractions yielded  20 g of RNA for the majority of each fraction. 
Nuclear RNA obtained from the U6 shRNA 5, tRNALys3 and tRNALys3 shRNA 5 fractions 
yielded <1 g and there was no detectable RNA when the samples were subjected 
polyacrylamide gel electrophoresis (Appendix C.14).  
 
Figure 3.17 indicates the processed guide strand detected as a band of  21 nt. The guide 
strand was detected in the total and cytoplasmic RNA of U6 shRNA 5 and in the total, 
nuclear and cytoplasmic RNA for H1 shRNA 5. As indicated in the polyacrylamide gel, 
there was no detectable RNA for U6 shRNA 5 nuclear fraction hence no detectable 
processed guide within the nuclear lane. U6 and H1 precursors were detected.  
Hybridisation of a radiolabelled probe complementary to U6 snRNA detected 
contamination of nuclear RNA within the cytoplasmic fractions of U6 shRNA 5, U6+1, H1 
shRNA 5 and H1 Mock, indicating lysis of the nuclei during the fractionation. The U6 probe 
confirmed equal loading of the total RNA between the samples, and equivalent loading of 
the nuclear and cytoplasmic fractions. Hybridisation of a radiolabelled probe 
complementary to tRNA detected RNA within the cytoplasmic fraction but no cytoplasmic 
RNA was detected in the nuclear fractions. There were two bands observed in the 
cytoplasmic fraction, which is likely due to different RNA species or non-specific binding.  
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Figure 3.17: Northern blot hybridisation of U6 and H1 processed anti-HBV effecter 
sequences of total, cytoplasmic and nuclear RNA.  
Total, nuclear and cytoplasmic RNA were extracted from Huh7 cells transfected with U6 and H1 
shRNA 5 and complementary U6+1 and H1 Mock plasmids. Hybridisation of a radioactively labeled 
probe detected processed anti-HBV guide 5 at 21 nucleotides. Precursors of the processed 
products were detected (purple arrow). The blot was stripped and probed for U6 snRNA, confirming 
RNA loading control. The blot was stripped and reprobed for tRNA. (T) - Total; (N) - Nuclear; (C) - 
Cytoplasmic. Huh7 cells were transfected using calcium chloride and fractionated using the 
PARIS™ kit.  
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Figure 3.18 indicates the processed guide strand detected as a band at 21 nucleotides 
for tRNALys3 shRNA 5 in the total and cytoplasmic fraction and for pri-miRNA-122/5 in the 
total RNA. There were no detectable bands for the pri-miRNA-122/5 nuclear or 
cytoplasmic fractions, even after 12 days exposure. The lack of processed guide within the 
tRNALys3 shRNA 5 nuclear fraction correlates with the lack of detectable RNA as identified 
in the polyacrylamide gel. Precursors were detected in the total and cytoplasmic fractions 
of tRNALys3 shRNA 5. Hybridisation of a radiolabelled probe complementary to U6 snRNA 
detected contamination of nuclear RNA within the cytoplasmic fractions of tRNALys3 shRNA 
5, tRNALys3 Mock, pri-miRNA-122/5 and pCI-neo. There was no nuclear RNA detected in 
the nuclear fractions of tRNALys3 Mock and tRNALys3 shRNA 5, which corroborates the lack 
of RNA isolated from the fraction. The U6 probe confirmed equal loading of the total RNA 
between the samples. Hybridisation of a radiolabelled probe complementary to tRNA 
detected RNA within the cytoplasmic fraction but no cytoplasmic RNA was detected in the 
nuclear fractions. 
 
Taken together these findings indicate that the nuclei are being lysed during the 
fractionation step, causing contamination within the cytoplasmic fractions. The cytoplasmic 
fraction, however, is removed in its entirety without contaminating the nuclear fraction.  
 
 
 
 
 
 
 
 
 
 
 
Assessing the efficacy of RNA Pol II- and RNA Pol III- promoter-driven effecter cassettes targeted to HBx 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Northern blot hybridisation of processed tRNA
Lys3
 and pri-miRNA-122/5 anti-HBV 
effecter sequences of total, nuclear and cytoplasmic RNA.  
Hybridisation of a radioactively labeled probe detected processed anti-HBV guide 5 at 21 
nucleotides. Precursors of tRNA
Lys3
 were identified (blue and green arrow). The blot was stripped 
and probed for U6 snRNA, confirming RNA loading control and the contamination of nuclear RNA in 
the cytoplasmic fractions. The blot was stripped and reprobed for tRNA. (T) - Total; (N) - Nuclear; 
(C) - Cytoplasmic. Huh7 cells were transfected using calcium chloride and fractionated using the 
PARIS™ kit. 
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3.10  Inhibition of HBV within an In vivo Mouse model  
3.10.1 Kaplan-Meier survival curve of mice post hydrodynamic tail vein injection 
It has been established that the RNA Pol III promoter-driven shRNA 5 effecter sequences 
and the pri-miRNA-122/5 shuttle are highly efficacious at knocking down the expressed 
target HBx, and at inhibiting production of viral antigens in vitro. To assess whether the 
effect would be as efficient in an in vivo model, eight groups of five mice each (n=40) were 
hydrodynamically injected (HDI) via the tail vein with, either the U6, H1 or tRNALys3 shRNA 
5 expression cassettes, pri-miRNA122/5 shuttle sequence or comparable mock plasmids 
(U6+1; H1 Mock, tRNALys3 Mock and pCI-neo) and pCH-9/3091. The administrations of the 
HDIs were scored out of 5, which provided an indication for delivery efficacy (data not 
shown). Twenty-four hours post HDI, four mice had died (Figure 3.19). The Kaplan-Meier 
survival curve indicates a 20% survival decrease in the experimental group U6 shRNA 5 
and control group U6+1. A 40% survival decrease was observed in the control group 
tRNALys3 Mock. All mice were sacrificed on day 5.  
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Figure 3.19: Kaplan-Meier survival curves of the hydrodynamically injected mice.  
Eight groups of five mice each were hydrodynamically injected via the tail vein. Four groups 
received either U6 shRNA 5 (purple); H1 shRNA 5 (blue); tRNA
Lys3
 shRNA 5 (green) expression 
cassettes or pri-miRNA-122/5 shuttle (pink), whilst the remaining four groups served as controls 
and received the corresponding mocks (black). Twenty-four hours post injection four mice had died. 
Two mice were from the tRNA
Lys3
 Mock group and one mouse each from the U6 shRNA 5 and 
U6+1 groups. The surviving mice were sacrificed on day 5 p.i.  
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3.10.2 Inhibition of HBsAg secretion 
Inhibition of HBsAg by the anti-HBV effecter sequences was measured in sera of HDI mice 
on 3 and 5 days post injection. The differences in the concentrations of HBsAg were 
measured between the anti-HBV effecter sequence and the mock for comparison. On day 
3, U6 shRNA 5 (p<0.005) and tRNALys3 shRNA5 (p<0.005) indicated a >95% decrease of 
serum HBsAg concentration whilst H1 shRNA 5 (p<0.005) and miRNA-122/5 (p<0.005) 
resulted in inhibition >80% (Figure 3.20). On day 5, U6 shRNA 5 (p<0.005) and pri-
miRNA-122/5 (p<0.005) inhibited HBsAg secretion to approximately 80%, which is 
decreased in comparison to day 3. H1 shRNA 5 (p<0.005) and tRNALys3 shRNA 5 
(p<0.005), continued to inhibit HBsAg secretion, by 85% and 98% respectively. The ability 
of the RNA Pol III promoters, H1 and tRNALys3 to increase the inhibition of HBsAg over five 
days suggests the effecter sequences are being transcribed at a rate comparable to the 
transcription of the virus. 
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Figure 3.20: Decrease of serum HBsAg in mice following HDI treatment.  
Plasmid DNAs containing the anti-HBV effecter sequences or complementary mocks were co-administered with the target vector pCH9/3091 to 
mice by hydrodynamic tail vein injection. Inhibition of HBsAg secretion in mouse sera was measured 3 and 5 days post injection. Error bars 
indicate the standard error of the mean (n=36). *p<0.05. The p-values are discussed within the text. 
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3.10.3 Detection of total HBV, cccDNA and rcDNA 
To assess the amount of circulating viral particles within the sera of the HDI treated mice, 
primer sets were used to amplify the preS1 region and the concentration determined using 
a pre-designed standard curve. The minimum detection limit for total HBV was determined 
at 84 copies (9). The only significant difference was observed on day 3 between tRNALys3 
shRNA 5 and the tRNALys3 Mock (p<0.05) (Figure 3.21) which correlates with the increased 
inhibition of HBsAg by tRNALys3 shRNA 5. There was no statistical significance observed 
day 5 for any of the anti-HBV effecter sequences. 
 
The data shows a clear trend in the amount of detectable HBV DNA, which is comparable 
to the trend observed in HBsAg inhibition. Decreases in the amount of HBV DNA were 
observed in all the Mock treated animals on day 5 indicating the probable clearing of the 
virus by the mice’s natural immune system. In addition there is an increase in HBV DNA 
observed on day 5 for U6 shRNA 5 and pri-miRNA-122/5, and a decrease observed for H1 
and tRNALys3.  
 
To assess the amount of total HBV, cccDNA and rcDNA in the liver, extracted DNA was 
analysed using an in house assay (2). Initially, the efficacies at which the target vector and 
DNA expressing plasmids were delivered to the liver following HDI were determined by 
amplification the Renilla luciferase. The delivery was variable between the eight groups, up 
to 1.5 fold difference (Appendix C.15). However, for the mock and experimental groups of 
the H1, tRNALys3 and CMV promoters, the delivery is relatively consistent within each 
group itself and then between the two groups. Delivery of the U6 shRNA 5 group was 
almost 1 fold lower when compared to the U6+1 group.  
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Total HBV DNA and cccDNA was quantified, and the amount of rcDNA obtained by 
subtracting cccDNA from total HBV. There was no visual difference in the amount of total 
HBV and rcDNA observed between the U6 +1 and U6 shRNA 5 groups (Figure 3.22), 
however a decrease was observed in the experimental groups for H1(Figure 3.22), 
tRNALys3 and pri-miRNA-122/5 (Figure 3.23). Although a decrease is evident, there was no 
significant difference observed between each of the control and the relative experimental 
groups, for either the total, cccDNA or rcDNA.  
 
The data indicates the same trend, which has been observed throughout the in vivo 
experiments, essentially indicating a decrease in HBV DNA due to the inhibition of 
replication by the effecter sequences. 
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Figure 3.21: Quantification of total HBV DNA isolated from livers of mice subjected to HDI.  
Hydrodynamic tail injections were used to co-administer pCH9/3091 and the shRNA expression cassette, pri-miRNA shuttle or complementary 
mocks. Total HBV was detected in the sera collected from mice on day 3 and day 5. The minimum detection limit (red line) of viral particles was 84 
copies per microlitre. Error bars indicate the normalised standard error of the mean (n=36). *p<0.05. 
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Figure 3.22: Quantification of U6 and H1 total HBV, cccDNA and rcDNA isolated from livers of mice subjected to HDI.  
The amount of rcDNA was quantified in the liver of HDI mice treated using the HDI procedure. There was no significant difference between the 
control and experimental groups, however a trend of decrease is observed between H1 Mock and H1 shRNA 5 injected mice. The amount of 
rcDNA within the liver constitutes the majority of the total HBV DNA. Error bars indicate the standard normalized error of the mean (n=3). 
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Figure 3.23: Quantification of tRNA
Lys3
 and CMV total HBV, cccDNA and rcDNA isolated from livers of mice subjected to HDI.  
There was no significant difference between the control and experimental groups, however the amount of rcDNA within the liver constitutes the 
majority of the total HBV DNA. Error bars indicate the standard normalized error of the mean (n=3). 
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4   DISCUSSION 
Harnessing of the endogenous RNAi pathway through the introduction of exogenous 
effecter cassettes to target conserved regions within the HBV genome is proving to be a 
substantially effective approach to antiviral gene therapy.  
 
McCaffrey et al (37) pioneered the initial use of RNAi in vivo to effectively target HBV. 
shRNAs with a guide sequence 25 bp in length and driven by the human U6 promoter 
were designed to target the four genes (core antigen, surface antigen, polymerase and X 
protein). The investigation showed a decrease of between 75-99% in HBV DNA, RNA, 
HBsAg and HBcAg. Numerous investigations into identifying a potent RNAi target, utilising 
different promoters (human U6 and H1 and mouse U6) to drive variable length shRNA 
constructs (reviewed in (21)) followed these initial findings. In 2006, Carmona et al (5) 
demonstrated effective inhibition of a particular HBV genotype in cultured cells and 
subsequently in an in vivo model. A potent RNAi sequence, which can rapidly silence 
target genes is essential in mediating effective knockdown of the virus.  
 
In 2006, the effects of long-term shRNA expression in mice were assessed by (22). 
Following the administration of an AAV vector capable of continuously expressing shRNAs 
(200 copies per cell) targeted to HBV, dose-dependent liver injury and subsequent death 
were observed. It was determined that the exogenous shRNAs were competing with the 
endogenous miRNAs causing saturation of the RNAi pathway.  
 
The current investigation aimed to assess the efficacy of three different Pol III promoters 
and a Pol II promoter to drive the expression of five different effecter cassettes targeted to 
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the conserved regions of HBx, without causing saturation of the endogenous RNAi 
pathway.  
 
4.1 Efficacy of RNA Pol II and RNA Pol III promoter-driven effecter 
cassettes 
In this study, the ability of five expression cassettes, each driven by one of four different 
promoters, to knockdown the HBx target was assessed. A definitive trend in target 
knockdown was established between the Pol III promoters U6, H1 and tRNALys3 driving the 
effecter sequences targeting nucleotides 1575-1599 (shRNA 5). The effecter sequence 
targeting nucleotides 1580-1604 (shRNA 6) which has a 19 nucleotide overlap with shRNA 
5 were effective in targeting HBx when driven by the U6 and H1 promoters. Similarly, the 
in vitro assay assessing the inhibition of HBsAg revealed that shRNA 5; pri-miRNA-122/5; 
shRNA 6 and pri-miRNA-122/6 caused significant inhibition, which was consistent with 
each of the four Pol II and Pol III promoters. Taken together it is clear that the effecter 
sequence cleaved from the shRNA 5 expression cassettes and pri-miRNA-122/5 shuttle 
were the greatest inhibitors of HBV, which correlates with previous findings (5, 15).  
 
Published findings have generally compared U6 promoter-driven effecter cassettes with 
H1, tRNALys3 or CMV promoter-driven effecter cassettes. There have been no 
investigations comparing efficacy of four different promoters expressing anti-HBV effecter 
sequences. Establishing the efficacy of these promoters to drive expression cassettes is 
important in that the lowest concentration of effecter required to cause optimal knockdown 
can be established. Furthermore, it is important to determine whether the expressed 
cassettes result in off-target or saturation effects due to the level of expression within a 
cell. The knockdown assays established that the effecter cassettes driven by the Pol III 
promoters U6 and H1 were the most efficacious in targeting HBV, however knockdown by 
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tRNALys3 proved to be as effective as U6 and H1 when expressing shRNA 5. These data 
demonstrated that even when expressed at a lower level, the ability of the effecter 
sequence to target HBV was maintained, which is significant when considering a construct 
for utilisation in antiviral gene therapy.   
 
4.2 Saturation and off-targeting 
The endogenous RNAi pathway was assessed for potential saturation by the most 
effective exogenous effecter cassettes generated in this investigation. No derepression of 
the miR-16 target expression by the exogenous cassettes was observed, confirming there 
was no interference with the endogenous RNAi pathway. Notably, U6 shRNA 5 and 
tRNALys3 shRNA 5 caused the least amount of interference. This was an important 
observation in that it demonstrated that at a high (U6 shRNA 5) and low level of 
expression (tRNALys3 shRNA 5) there was no endogenous saturation. Taken together, this 
corroborates the previous findings in demonstrating the importance and usefulness of 
tRNALys3 shRNA 5 as a suitable construct for antiviral gene therapy.  
 
4.3 Processing of shRNA and pri-miRNA expression cassettes 
Hybridisation of a radiolabelled probe complementary to the anti-HBV guide sequence 
detected processed products at 21 nt, demonstrating the processing of the guide strand 
from each of the promoter-driven expression cassettes occurred according to the intended 
design. Furthermore, the detection of these processed products showed that the guide 
strand was being selected for the incorporation into RISC. The expression level and 
processing of the guide strands from the U6 shRNA 5 and pri-miRNA-122/5 cassettes, 
assessed by northern blot hybridisation supported previous findings (15). The expression 
levels of the H1 and tRNALys3 shRNA 5 precursors were considerably lower when 
compared to U6 shRNA 5 precursor. These findings support the notion that H1 and 
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tRNALys3 express at a lower level. Notably, the precursor denoting the pre-tRNALys3-shRNA 
5 demonstrated no effect on the processing of the shRNA, or the guide sequence from the 
tRNA. Notably, the majority of the expressed U6 shRNA 5 was not processed, indicating 
the inability of Dicer to process the shRNAs as quickly as they were transcribed. Although 
there was no detectable saturation of the endogenous RNAi pathway at 48 hours, the 
accumulation of these shRNAs could cause potential interference in the export pathway 
following long-term expression. H1 and tRNALys3 shRNA 5 were processed at lower level, 
which allowed for the majority of the effecter cassettes to be processed. Pri-miRNA-122/5 
was processed at a rate equivalent to that of effecter cassette expression, which 
supported previous findings (15). 
 
Comparative analysis of the nuclear and cytoplasmic compartments for the presence of 
processed effecter cassettes proved challenging. Contamination of the cytoplasmic 
fraction with nuclear RNA occurred within every fractionation, suggesting lysis of the nuclei 
prior to separation of the fractions. The initial lysing of the plasma membrane may cause 
indirect lysis of the nuclei through the shearing forces associated with the resuspension of 
the cell pellet with the lysis buffer. Alternatively, centrifugation of the mixture may cause 
released intact nuclei to lyse. The findings established that the majority of the expressed 
cassettes were localised within the cytoplasm and not the nucleus, which was expected as 
the shRNAs are transported out of the nucleus by exportin-5 and processed by Dicer in the 
cytoplasm of cells.  
  
4.4 In vivo Efficacy 
Previous comparisons between U6 and tRNALys3 expressed effecter cassettes by Scherer 
et al (45) demonstrated a comparable efficacy of Dicer processing and incorporation of the 
guide strand into the RISC complex between the expressed constructs. Furthermore, the 
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comparison of U6 and tRNAVal expressed effecter cassettes by Kawasaki in 2003 (27) 
established the processing of the tRNA-dsDNA to be significantly efficacious. Taken 
together these findings are supported by the data obtained after transfection of cells in 
culture, which identified U6 shRNA 5 and tRNALys3 shRNA 5 as the most efficacious anti-
HBV effecter cassettes.  
 
The possibility exists that the established efficacy of an anti-HBV effecter cassette found to 
function optimally in vitro could function with less efficacy when introduced to an in vivo 
environment. In vivo analysis of the shRNA 5 expression cassettes and pri-miRNA-122/5 
shuttle substantiated this hypothesis. The knockdown efficacy by U6 shRNA 5 and pri-
miRNA-122/5 proved effective for an initial 72 hours, however the inability of the effecter 
cassette to maintain consistent knockdown was evident 120 hours post injection. As 
previously found, U6 is a highly potent promoter and the effecter sequences are incapable 
of being processed at a rate equivalent to that at which they are expressed. Based on this, 
it can be deduced that the increased amount of exogenous shRNAs within the cytoplasm 
of cells resulted in the activation of the innate immune response. Alternatively, it could be 
associated with the variable delivery of DNA to the liver. H1 and tRNALys3 shRNA 5 which 
are expressed at a consistently low level, caused significant inhibition of HBV in sera 72 
hours post injection, which continued to increase 120 hours post injection. The increase in 
inhibition indicates the shRNAs are being expressed at a rate, which is optimal for the 
processing machinery of the endogenous RNAi pathway. These findings were supported 
by the observations in the liver of the mice. Overall, the in vivo findings found RNALys3 to 
be the most effective in targeting HBV, which supported the findings observed in cultured 
cells. 
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5 CONCLUSIONS 
The preliminary investigation has found tRNALys3 shRNA 5 to be the most effective 
expression cassette to target and silence HBV in vitro and in vivo when compared the 
remaining RNAi effecter sequences. The ability of tRNALys3 to express the effecter 
cassettes at a lower level whilst maintaining knockdown which was comparable to stronger 
promoters (U6 and CMV) and at times more efficient than these promoters, has defined 
the importance of this construct as a novel approach towards antiviral gene therapy. The 
primary in vivo investigations provided an insight into how exogenous expression 
cassettes function within a living organism expressing HBV over a short period of time. A 
plethora of investigations have assessed short-term expression of effecter cassettes, 
however the efficacy and duration of expression should be assessed over extended time 
periods.  
 
The investigation identified the RNAi effecter sequences (5 and 6) to be highly effective in 
targeting and inhibiting HBV when assessed in cell culture. The ability of these effecter 
sequences to silence HBV even when expressed at lower levels by H1 and tRNALys3 
demonstrated the potency of these expression cassettes. This is of importance, as it 
supports the requirement of optimal silencing at lower expression levels.  
 
 It would be advisable to assess the effects of tRNALys3 shRNA 5 in a transgenic mouse 
model, which actively expresses HBV. Alternatively, a natural host of HBV such as the 
woodchuck would prove even more efficacious as an in vivo model. This would allow a 
baseline of initial infection (circulating viral particles) to be established before administering 
the therapeutic construct. Furthermore, as this investigation has shown, a lower target to 
effecter ratio (1:0.1) was as effective as a higher target to effecter ration (1:10) at knocking 
down HBV, thus administration of a lower effecter dose warrants investigation.   
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Antiviral gene therapy is redirecting the way research therapeutics is approached. There 
are particular aspects associated with the treatment by antiviral gene therapy, which 
require further research. A combinatorial approach investigating the effects of combining 
H1 and tRNALys3 promoter-driven effecter cassettes could be assessed. Combinatorial 
therapy of multi expressing cassettes would allow two different effecter sequences to be 
individually expressed by a low transcriptional promoter and may prove more effective in 
long-term therapy. Furthermore, combinatorial therapy has the important advantage of 
limiting the emergence of escape mutants because multiple gene sites are targeted, which 
renders it unlikey that the virus could mutate at all of the target sites. The delivery of 
therapeutic constructs to liver is of particular importance. The introduction of exogenous 
effecter cassettes via viral vectors, (adenoviruses, AAVs and lentiviruses), is being 
pursued as a possible vehicle for site-specific delivery. Adenoviruses and AAVs are 
particularly efficient in transducing hepatocytes, which would allow stable expression of the 
effecter sequences at a localised area, thereby prohibiting toxicity effects (20, 22). 
Exploitation of the RNAi pathway is paving the way in therapeutic approaches (42), and an 
advance in targeting HBV is progressing. 
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APPENDIX A 
A.1 Preparation of Agarose Gels 
Agarose (WhiteSci, Cape Town, RSA) was weighed into a clean 500 ml Erlenmeyer flask 
and reconstituted with 1× Tris-acetate-EDTA (TAE) buffer (Appendix A.1.1). The mixture 
was boiled to ensure complete dissolution of the agarose before being poured into a 
prepared casting tray and allowed to set. The samples, which were to be subjected to 
electrophoresis, were mixed with 6× Orange Loading Dye (Fermentas, MD, USA) at a ratio 
of 1:5 and loaded into the wells of the gel. Ten microliters of O’Gene Rule 100 bp DNA 
ladder (Fermentas, MD, USA) was always loaded into lane 1 of the gels. The DNA 
fragments were viewed under UV light and the resultant images captured (Gel Logic 200 
Imaging System, Kodak, NY, USA). 
 
A.1.1 50× Tris-acetate-EDTA (TAE) Buffer 
Tris base (240 g) was dissolved in 500 ml sterile water. One hundred millilitres of EDTA 
(0.5 M; pH 8.0) and 57 ml glacial acetic acid were added and the buffer was made up to 
1000 millilitres with sterile water. The buffer was stored at room temperature. To prepare 
1× TAE buffer, 20 ml of 50× TAE buffer was added to 980 ml sterile water (40 mM Tris-
acetate; 1 mM EDTA). 
 
A.2 Extraction of DNA - Qiagen MinElute™ Gel Extraction  
The weight of the agarose gel slice was determined and three times the volume of Buffer 
QG added and the solution incubated in a dry heating block at 42°C for 15 minutes. The 
microcentrifuge tube was vortexed every two minutes. Once the gel slice was completely 
dissolved, isoproponal equal to the weight of the gel slice was added and the 
microcentrifuge tube gently inverted ten times to ensure thorough mixing. The sample 
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mixture was transferred into a MinElute™ column, which had been placed in a collection 
tube. The MinElute™ column was centrifuged at 16 000 × g for one minute allowing the 
DNA to bind to the column. The flow-through was discarded and 500 µl Buffer QG was 
added to the column. The column was centrifuged for one minute, the flow-through 
discarded and 750 µl Buffer PE added. The column was centrifuged for one minute and 
the flow-through discarded. The column was centrifuged again for one minute to ensure 
any residual ethanol from the Buffer was removed. The MinElute™ column was 
transferred to a sterile microcentrifuge tube and 20 µl Buffer EB was added to the centre of 
the column membrane to ensure the maximum yield of DNA was recovered. The 
MinElute™ column was centrifuged for one minute before being discarded. Working stocks 
were prepared from the purified DNA and stored at -20°C.  
 
A.3 Preparation of Chemically Competent DH5-α E.coli Cells 
A culture of bacterial cells was prepared by adding 50 µl of either DH5-α or XL1-blue stock 
to 10 ml of LB (Appendix A.3.1) before overnight incubation in a shaking incubator at 37°C. 
A control culture containing ampicillin (Appendix A.3.2) at a final concentration of 100 
µg/ml was included. A 1:50 ratio of overnight culture and fresh LB broth was prepared in 
50 ml Falcon tubes and incubated for two hours in a shaking incubator at 37°C. The tubes 
were centrifuged at 1200 × g for 15 minutes. The supernatant was removed and the pellet 
resuspended in 1 ml transformation buffer (Appendix A.3.3). The resuspension mixture 
was made up to 20 ml with transformation buffer and incubated on ice for 30 minutes 
before being centrifuged at 760 × g for 10 minutes at 4°C. The supernatant was removed 
and the pellet resuspended in 1.5 ml transformation buffer. One hundred microlitre aliquots 
were prepared and stored at -70°C. 
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A.3.1  Luria-Bertani Broth (LB Broth)  
Bacto-tryptone (10 g), yeast extract (5 g) and NaCl (5 g) were dissolved in 1000 ml sterile 
water. The broth was autoclaved and stored at room temperature. 
 
A.3.2 1000× Ampicillin  
One gram of ampicillin was dissolved in a mixture of 5 ml ethanol and 5 ml sterile water 
and stored at -20°C. 
 
A.3.3 Transformation Buffer  
CaCl2.2H2O (1.4702 g), PIPES.HCl (0.3024 g) and 15 ml glycerol were dissolved in 80 ml 
sterile water. The solution was adjusted to pH7.00 with NaOH. The buffer was made up to 
100 ml with sterile water and autoclaved. The buffer was stored at -20°C. 
 
A.4 LB Amp Agar Plates  
Ten grams of agar was dissolved in 1000 ml LB broth, autoclaved and cooled to 50°C. 
Ampicillin was added to the LB agar to a final concentration of 100 µg/ml before being 
poured into sterile Petri dishes. The plates were stored at 4°C until required 
 
A.5 X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside)  
Twenty milligrams of X-gal was dissolved in 1 ml dimethyl formamide and stored at -20°C 
in foil. 
A.6 IPTG (isopropyl thiogalactoside)  
One hundred milligrams of IPTG was dissolved in to 1 ml sterile water, filter sterilised and 
stored at -20°C. 
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A.7 Blue-white Screening 
pTZ57R incorporates the lac operon, which is induced by IPTG to express β-
galactosidase. This enzyme metabolises lactose substrates into galactose and glucose 
products. X-gal is a modified colourless galactose sugar, which releases blue products 
during enzymatic breakdown. The insertion of DNA into the MCS of pTZ57R causes a 
disruption in the lacZ gene, which results in production of dysfunctional β-galactosidase. 
The inability of the dysfunctional β-galactosidase to metabolise X-gal causes the colony to 
remain white, which allows colonies transformed with successfully cloned plasmids to be 
identified. 
 
A.8 Extraction of pDNA - Roche High Pure Plasmid Isolation  
Four milliliters of LB was inoculated with a colony containing the plasmid of interest and 
incubated overnight at 37°C. The tubes were centrifuged at 1200 × g for 15 minutes to 
pellet the bacterial cells. The supernatants were discarded and the tubes blotted on paper 
towel to remove any residual broth. The pellets were gently resuspended in 250 µl 
Suspension Buffer and transferred to sterile microcentrifuge tubes. The bacterial cells 
were lysed with 250 µl Lysis Buffer and the microcentrifuge tubes were inverted ten times 
to ensure thorough mixing. The lysis reaction was neutralised with 350 µl chilled 
Neutralisation Buffer and the microcentrifuge tubes inverted to ensure thorough mixing. 
The microcentrifuge tubes were centrifuged at 16 000 × g and the supernatants transferred 
into a High Pure Filter tube, which had been placed in a collection tube. The filter tubes 
were centrifuged at 16 000 × g for one minute, allowing the DNA to bind to the columns. 
The flow-through was discarded and 700 µl Wash Buffer I added to the columns. The 
columns were centrifuged at 16 000 × g for one minute and the flow-through discarded. 
The columns were centrifuged at 16 000 × g for one minute to ensure any residual ethanol 
Assessing the efficacy of RNA Pol II- and RNA Pol III- promoter-driven effecter cassettes targeted to HBx 
 
108 
from the Wash Buffer I was removed before being transferred to sterile microcentrifuge 
tubes. One hundred microlitres Elution Buffer was added and the columns centrifuged at 
16 000 × g for one minute. DNA working stocks of 100 ng/µl were prepared and stored at -
20°C. The concentrations of DNA (ng/µl) were measured at 260 nm. 
 
A.9 Automated Cycle Sequencing 
Specific PCR amplicons were sequenced on a SpectruMedix model SCE 2410 automated 
sequencer (SpectruMedix, State College, PA) using the ABI Big Dye Terminator Cycle 
Sequencing Kit (Applied Biosystems, CA, USA) according to manufacturers instructions 
(Appendix A.9.1). Briefly, the PCR products were sequenced using the M13 forward 
primer, which determined the sequence region preceding the expression cassettes and 
pri-miRNA shuttle sequences (Inqaba, Pretoria, RSA).  
 
A.9.1 ABI Big Dye Terminator Cycle Sequencing Kit 
The amplicons to be sequenced were prepared in a final reaction volume of 10 µl 
containing 100 ng plasmid DNA, 2 µl 2.5× Ready Reaction Premix, 1 µl 5× BigDye 
Sequencing Buffer and 10 pmol M13 forward or reverse primers. The PCR was 
programmed to run with an initial denaturation at 96°C for 1 minute with 25 cycles of 
‘sequencing’ PCR (denaturation at 96°C for 10 seconds; annealing at 50°C for 5 seconds 
and elongation at 60°C for four minutes).  
 
A.10 Isolation of Plasmid DNA by standard Alkaline Lysis 
Four millilitres of LB broth was inoculated with a single bacterial colony containing the 
plasmid of interest and incubated overnight at 37°C. The cultures were centrifuged at 1200 
× g for 15 to pellet the bacterial cells. The supernatants were discarded and the tubes 
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blotted on paper towel to remove any residual broth. The pellets were gently resuspended 
in 300 µl resuspension buffer (50 mMTris-HCl, pH 8.0; 10 mM EDTA and 100 µg/ml 
RNase A) and transferred to sterile microcentrifuge tubes. The bacterial cells were lysed 
with 300 µl of lysis buffer (1% SDS (w/v); 200 mM NaOH) and the microcentrifuge tubes 
were inverted ten times to ensure thorough mixing. The lysates were neutralised with 300 
µl chilled neutralisation buffer (3.0 M potassium acetate, pH 5.5) and the microcentrifuge 
tubes inverted ten times to ensure thorough mixing before being centrifuged at 16 000 × g 
for 20 minutes at 4°C. The supernatant was transferred into a sterile microcentrifuge tube 
and 750 µl isoproponal was added. The microcentrifuge tubes were inverted ten times to 
ensure complete mixing before being stored overnight at -20°C. The DNA was pelleted by 
centrifugation at 16 000 × g for 30 minutes at 4°C. The supernatant was removed and 250 
µl 70% ethanol was added. The microcentrifuge tubes were centrifuged at 16 000 × g for 5 
minutes. The ethanol was removed and the DNA pellet allowed to air dry. The pellet was 
resuspended in 50 µl nuclease free water and the DNA stored at -20°C. The 
concentrations of DNA (ng/µl) were measured at 260 nm. 
 
A.11 Promega Dual Luciferase™ Assay  
The media was removed from transfected cells and the cells lysed with 100 µl 1 × Passive 
Lysis Buffer and incubated for 20 minutes at 37°C. The lysed cells were aspirated and 10 
µl of each sample was added into a 96 well microplate (Corning, MA, USA). The required 
amount of Luciferase Assay Reagent II (LAR II), which measures the Firefly luciferase 
expression, was calculated at 50 µl/well. The required amount of Stop ’n Glo Reagent, 
which measures the background expression of Renilla luciferase, was calculated at 50 
µl/well. The ratio of Firefly luciferase to Renilla luciferase was measured using the Veritas 
Microplate Luminometer (Turner Biosystems, CA, USA). 
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A.12 HBsAg Detection - MONOLISA® Ag HBs PLUS Kit 
One hundred microlitres of positive control (R4), 100 µl negative control (R3) and 100 µl of 
samples were aliquoted into the appropriate microplate wells. Fifty microlitres of conjugate 
solution (R6 and R7) was dispensed into the sample-containing wells. The plate was 
covered in adhesive film and incubated at 37°C for one hour followed by washing with a 
PW40 microplate washer (Sanofi Pasteur Diagnostics, MN, USA) using 1× Wash solution 
(R2) on the TO2 N5B0.5s 800 cycle. The enzymatic development solution was prepared 
(R8 and R9) and 100 µl dispensed into each well. The microplate was incubated in the 
dark, at room temperature for 30 minutes before 100 µl of stopping solution (R10) was 
dispensed into the wells. The microplate was read at an optical density of 490/655 nm. 
 
A.13 Calcium chloride (2.5 M) 
CaCl2.2H2O (183.7 g) was dissolved in 500 ml sterile water. The solution was sterilised 
through a 0.45 µm filter and stored at -20 °C. 
 
A.14 2 × HEPES Buffer 
NaCl (16.4 g), HEPES (11.9 g) and Na2PO4 (0.21 g) were dissolved in 800 ml sterile 
water. The solution was adjusted to pH 7.05 with NaOH and the volume made up to 1000 
ml with sterile water. The solution was sterilised through a 0.45 µm filter and stored at -20 
°C. 
 
A. 15 Cellular Fractionation Method 1 
Huh7 cells were prepared as previously described (Section 2.8). The supernatant was 
removed and the pellet resuspended in 375 µl ice-cold Lysis Buffer (100 mM NaCl; 5 mM 
MgCl2; 0.5% v/v Nonidet P-40; 50 mM Tris-HCl) and stored on ice for ten minutes. The 
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samples were centrifuged at 16 000 × g for two minutes at 4°C. The supernatant 
(cytoplasmic fraction) was aspirated and transferred to a sterile microcentrifuge tube. The 
pellet (nuclear fraction) was resuspended in 100 µl saline (19). RNA was isolated from the 
fractionations as previously described (Section 2.7). 
 
A.16 Cellular Fractionation Method 2 
Huh7 cells were prepared as previously described (Section 2. 8). The supernatant was 
removed and resuspended in 450 µl ice-cold Buffer A (10 mM HEPES, pH 7.9; 10 mM 
KCl; 1 mM DTT; 0.1 M EDTA, pH 8.0) and stored on ice for 25 minutes. The samples were 
centrifuged at 2300 × g for three minutes at 4°C. The supernatant (cytoplasmic fraction) 
was aspirated and transferred to a sterile microcentrifuge tube. The pellet (nuclear 
fraction) was resuspended in 100 µl saline (23). RNA was isolated from the fractions as 
previously described (Section 2.7). 
 
A.17 Cellular Fractionation Method 3 
Huh7 cells were prepared as previously described (Section 2. 8). The supernatant was 
removed and the pellet resuspended in one millilitre of ice-cold Buffer A (10 mM HEPES, 
pH 7.9; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM DTT) and stored on ice for five minutes. 
Resuspended cells were homogenised with 20 strokes of a sterile pre-chilled Dounce 
homogeniser and transferred to a sterile microcentrifuge tube. The samples were 
centrifuged at 100 × g for five minutes at 4°C. The supernatant was removed and retained 
as the cytoplasmic fraction. The pellet containing the nuclear fraction was resuspended in 
600 µl Buffer S1 (0.25 M Sucrose; 10 mM MgCl2) and layered over 600 µl Buffer S3 (0.88 
mM Sucrose; 0.5 mM MgCl2). The nuclear fraction was centrifuged at 120 × g for ten 
minutes at 4°C. The cytoplasmic and nuclear fractions were resuspended in 200 µl and 
800 µl 1× RIPA Buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 0.5% 
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Deoxycholate) respectively and centrifuged at 120 × g for ten minutes at 4°C. (Protocol 
modified from (4)). The purified fractions were transferred into sterile microcentrifuge tubes 
and RNA isolated as previously described (Section 2.7). 
 
A.18 Extraction of RNA from nuclear and cytoplasmic fractions - 
PARIS™ Kit 
Two hundred and fifty microlitres of the lysate (nuclear or cytoplasmic) was added to 250 
µl 2 × Lysis/Binding solution in a sterile microcentrifuge tube and mixed gently by inverting 
the tubes four times. Two hundred and fifty microlitres of absolute ethanol was added to 
the mixture and the microcentrifuge tubes were inverted four times to ensure thorough 
mixing. The sample mixture was added to a Filter Cartridge assembled in a sterile 
Collection Tube and centrifuged at 500 × g for one minute at 25°C. The flow through was 
discarded, 700 µl of Wash Solution 1 added to the Filter Cartridge and centrifuged at 500 × 
g for one minute at 25°C. The procedure was repeated with 500 µl of Wash Solution 2 and 
then Wash Solution 3. The Filter Cartridge was placed into a sterile Collection Tube. Fifty 
microlitres of hot Elution Solution (95°C) was added to the Filter Cartridge in sequential 
aliquots of 40µl and 10 µl and centrifuged at 500 × g for 30 seconds at 25 °C. The 
extracted RNA fractions were stored at -80°C.  
 
A.19 Preparation of Polyacrylamide Gel  
The polyacrylamide gel was prepared in a volume of 60 ml. Bis-acrylamide (0.45 g) and 
acrylamide (8.55 g) were weighed into a clean 100 ml beaker. Thirty grams of Urea (8 M) 
was added with 6 ml 10 × Tris-borate-EDTA (TBE) buffer (Appendix A.19.1). The mixture 
was made up to 60 ml with sterile water. Prior to pouring the gel, 250 µl 1% (w/v) 
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Ammonium persulphate (APS) and 25 µl TEMED (tetramethylethylenediamine) were 
added to the mixture.  
 
A.19.1  10 × Tris-borate-EDTA (TBE) Buffer 
Boric acid (27.5 g); Tris-base (50 g) and 20 ml EDTA (0.5 M) were dissolved in 400 ml 
sterile water, and the solution adjusted to pH 8.0 with dilute HCl. The buffer was made up 
to 500 ml with sterile water, autoclaved and stored at room temperature. 
 
A.20 Radioactive labelling of Oligonucleotide Probes 
Oligonucleotide probes were radioactively labelled in a final reaction volume of 20 µl 
containing 2 µM probe, 2 µl PNK buffer A, 1 µl PNK (Fermentas, MD, USA) and 5 micro 
Curies (µCi) [γ-32P] ATP (185 kilo becquerel (kBq)) (SepSci, Johannesburg, RSA). The 
mixture was reconstituted in nuclease free water and incubated at 37°C for 45 minutes.  
 
A.21 20 × Saline-sodium citrate (SSC) Buffer 
Sodium chloride (175 g) and sodium citrate (88 g) were dissolved in 800 ml sterile water, 
and the solution was adjusted to pH 7.0 with HCl. The buffer was made up to 1000 ml with 
sterile water, autoclaved and stored at room temperature. To prepare 5× SSC buffer, 25 ml 
of 20× SSC buffer was added to 75 ml sterile water. To prepare a 1× SSC buffer, 5 ml of 
20× SSC buffer was added to 95 ml sterile water. 
 
A.22 Quantitative Real Time PCR – LightCycler® FastStart DNA 
MasterPLUS SYBR Green I Kit 
Fourteen microlitres of enzyme (1a) was added to the SYBR green Reaction Mix (1b) and 
gently mixed. The PCR was prepared in a final reaction volume of 20 µl containing 500 ng 
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DNA, 1 pmol forward primer, 15 pmol reverse primer, and was carried out in a 5× Master 
Mix. The LightCycler® Carousel-Based System Protocol was programmed as described in 
Table 6.1 (adapted from Roche LightCycler® FastStart DNA MasterPLUS SYBR Green I 
Kit). 
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Table 6.1: Quantitative Real Time LightCycler® PCR Protocol  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Program Cycles Segment Temperature Hold Time 
Hot Start 1 Denaturation 95°C 00:10:00 
Quantification 50 
Denaturation 
Annealing 
Elongation 
95°C 
60°C 
72°C 
00:00:10 
00:00:10 
00:00:10 
Melting Curve 1 
Denaturation 
Annealing 
Elongation 
95°C 
65°C 
95°C 
00:00:00 
00:01:00 
00:00:00 
Cool 1 Cooling 40°C 00:00:30 
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APPENDIX B - ANIMAL ETHICS CLEARANCE 
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APPENDIX C - SUPPLEMENTARY DATA 
 
 
 
 
 
Figure C.1: Verification of the generation of the H1 shRNA expression cassettes.  
The size of the completed H1 shRNA expression cassettes were verified to be 320 bp which 
correlates to the expected size of 315 bp.  
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H1 shRNA5 GGATCCGATTGATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCT 
H1 Promoter  ----------GATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCT 
H1 shRNA 5 R1 -------------------------------------------------- 
shRNA 5 R2     -------------------------------------------------- 
 
H1 shRNA 5   CCAAGGAATCGCGGGCCCAGTGTCACTAGGGCGGGAACACCCAGGCGCGC 
H1 Promoter   CCAAGGAATCGCGG-CCCAGTGTCACTAGG-CGGGAACACCCAG-CGCGC 
H1 shRNA 5 R1 -------------------------------------------------- 
   shRNA 5 R2  -------------------------------------------------- 
 
H1 shRNA 5   GGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCT 
H1 Promoter  G-TGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCT 
H1 shRNA 5 R1  -------------------------------------------------- 
   shRNA 5 R2  -------------------------------------------------- 
 
H1 shRNA 5  GCAATATTTGCATGTCACTATGTGTTCTGGGAAATCACCATAAACGTGAA 
H1 Promoter  GCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAA 
H1 shRNA 5 R1  -------------------------------------------------- 
   shRNA 5 R2 -------------------------------------------------- 
 
H1 shRNA 5   ATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGAT 
H1 Promoter ATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGAT 
H1 shRNA 5 R1 --------------------------------GTATGAGACCACTCGGAT 
   shRNA 5 R2  -------------------------------------------------- 
 
H1 shRNA 5  CCGTCGTGTGCGCTTTGCTTCGCCTCTGeCTTCCTGTCACAGAGGTGAAGC 
H1 Promoter   CC------------------------------------------------ 
H1 shRNA 5 R1 CCGTCGTGTGCGCTTTGCTTCGCCTCTGCTTCCTGTCACAGA-------- 
   shRNA 5 R2 -----------------------CTCTGCTTCCTGTCACAGAGGTGAAGC 
 
H1 shRNA 5 GAAGTGCACACGGTTTTTTACGCGTAGATCTGGGAATCTAGATGCATTCG 
H1 Promoter  -------------------------------------------------- 
H1 shRNA 5 R1 -------------------------------------------------- 
   shRNA 5 R2 GAAGTGCACACGGTTTTTTACGCGTAGATCTGGG---------------- 
 
 
Figure C.2: DNA sequence of H1 shRNA 5.  
The shRNA expression cassette is 100 % homologous to the designed primers. The promoter 
contains a G153A base change. Four base insertions were identified in the promoter region (red) 
however, these had no effect on transcription. The shRNA is comprised of the anti-guide sequence 
(blue), loop (green) and guide sequence with termination site (purple).   
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H1 shRNA 6 GATCCGATTGATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 Promoter    ---------GATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 shRNA 6 R1  -------------------------------------------------- 
   shRNA 6 R2  -------------------------------------------------- 
 
H1 shRNA 6    CAAGGAATCGGGGGGCCCGGGGTCACTTGGGGGGGAACACCCAGGGGCGC 
H1 Promoter   CAAGGAATCGCGG--CCCAGTGTCACTAGGCGGG-AACACCCAGCG-CGC 
H1 shRNA 6 R1 -------------------------------------------------- 
   shRNA 6 R2  -------------------------------------------------- 
 
H1 shRNA 6     GTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTG 
H1 Promoter    GTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTG 
H1 shRNA 6 R1  -------------------------------------------------- 
   shRNA 6 R2  -------------------------------------------------- 
 
H1 shRNA 6     CAATATTTGCATGTCACTATGTGTTCTGGGAAATCACCATAAACGTGAAA 
H1 Promoter    CAATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAAA 
H1 shRNA 6 R1  -------------------------------------------------- 
   shRNA 6 R2  -------------------------------------------------- 
 
H1 shRNA 6     TGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATC 
H1 Promoter    TGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATC 
H1 shRNA 6 R1  -------------------------------GTATGAGACCACTCGGATC 
   shRNA 6 R2  -------------------------------------------------- 
 
H1 shRNA 6     CGTACACCTCGCTTCACCTCTACACATCTTCCTGTCAACGTGCAGAGGTG 
H1 Promoter    C-------------------------------------------------  
H1 shRNA 6 R1  CGTACACCTCGCTTCACCTCTACACATCTTCCTGTCAACGT--------- 
   shRNA 6 R2  ----------------------CACATCTTCCTGTCAACGTGCAGAGGTG 
 
H1 shRNA 6     AAGCGAAGTGCATTTTTTACGCGTAGATCTAATCTAGATGCATTCGCGAG 
H1 Promoter    -------------------------------------------------- 
H1 shRNA 6 R1  -------------------------------------------------- 
   shRNA 6 R2  AAGCGAAGTGCATTTTTTACGCGTAGATCTGGG----------------- 
 
 
Figure C.3: DNA sequence of H1 shRNA 6.  
The shRNA expression cassette is 100 % homologous to the designed primers. There were three 
alterations observed within the H1 promoter. A double nucleotide insertion (GG) and two nucleotide 
changes, A65T and G153A. The shRNA is comprised of the anti-guide sequence (blue), loop 
(green) and guide sequence with termination site (purple).   
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H1 shRNA 8 GATCCGATTGATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 Promoter   ---------GATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 shRNA 8 R1  -------------------------------------------------- 
   shRNA 8 R   -------------------------------------------------- 
           
H1 shRNA 8   CAAGGAATCGCGGGCCCAGTGTCACTAGGGCGGGAACACCCAGCGCGCGT 
H1 Promoter  CAAGGAATCGCGG-CCCAGTGTCACTAGG-CGGGAACACCCAGCGCGCGT 
H1 shRNA 8 R1  -------------------------------------------------- 
   shRNA 8 R2  -------------------------------------------------- 
           
H1 shRNA 8     GCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCA 
H1 Promoter    GCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCA 
H1 shRNA 8 R1  -------------------------------------------------- 
   shRNA 8 R2  -------------------------------------------------- 
      
H1 shRNA 8     ATATTTGCATGTCACTATGTGTTCTGGGAAATCACCATAAACGTGAAATG 
H1 Promoter    ATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAAATG 
H1 shRNA 8 R1  -------------------------------------------------- 
   shRNA 8 R2  -------------------------------------------------- 
           
H1 shRNA 8     TCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATCCG 
H1 Promoter    TCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATCC- 
H1 shRNA 8 R1  -----------------------------GTATGAGACCACTCGGATCCG 
   shRNA 8 R2  -------------------------------------------------- 
           
H1 shRNA 8     CAACGTCAACAACCAACCTTGAAGCCTTCCTGTCAGCCTCAAGGTCGGTC 
H1 Promoter    -------------------------------------------------- 
H1 shRNA 8 R1  CAACGTCAACAACCAACCTTGAAGCCTTCCTGTCAGCCT----------- 
   shRNA 8 R2  --------------------GAAGCCTTCCTGTCAGCCTCAAGGTCGGTC 
           
H1 shRNA 8     GTTGACATTGTTTTTTACGCGTAGATCTGGGAATCTAGATGCATTCGCGA 
H1 Promoter    -------------------------------------------------- 
H1 shRNA 8 R1  -------------------------------------------------- 
   shRNA 8 R2  GTTGACATTGTTTTTTACGCGTAGATCTGGG------------------- 
 
 
Figure C.4: DNA sequence of H1 shRNA 8.  
The shRNA expression cassette is 100 % homologous to the designed primers. There were two 
single nucleotide insertions (G) at and a G151A base change observed within the H1 promoter. The 
shRNA is comprised of the anti-guide sequence (blue), loop (green) and guide sequence with 
termination site (purple).   
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H1 shRNA 9     AATCCGATTGATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 Promoter    ---------GATCGAATTCACTAGTGAACGCTGACGTCATCAACCCGCTC 
H1 shRNA 9 R1  -------------------------------------------------- 
   shRNA 9 R2  -------------------------------------------------- 
           
H1 shRNA 9     CAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGCGCGTG 
H1 Promoter    CAAGGAATCGCGG-CCCAGTGTCACTAGGCGGGAACACCCAGCGCGCGTG 
H1 shRNA 9 R1  -------------------------------------------------- 
   shRNA 9 R2  -------------------------------------------------- 
 
H1 shRNA 9     CGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAA 
H1 Promoter    CGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAA 
H1 shRNA 9 R1  -------------------------------------------------- 
   shRNA 9 R2  -------------------------------------------------- 
           
H1 shRNA 9     TATTTGCATGTCACTATGTGTTCTGGGAAATCACCATAAACGTGAAATGT 
H1 Promoter    TATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAAATGT 
H1 shRNA 9 R1  -------------------------------------------------- 
   shRNA 9 R2  -------------------------------------------------- 
 
H1 shRNA 9     CTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATCCGT 
H1 Promoter    CTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACTCGGATCC-- 
H1 shRNA 9 R1  ----------------------------GTATGAGACCACTCGGATCCGT 
   shRNA 9 R2  -------------------------------------------------- 
 
H1 shRNA 9     AAGAAGCTGTAGGCACAAATTAGTCTTCCTGTCAACCAATTTATGCCTAC 
H1 Promoter    -------------------------------------------------- 
H1 shRNA 9 R1  AAGAAGCTGTAGGCACAAATTAGTCTTCCTGTCAACCA------------ 
   shRNA 9 R2  --------------------TAGTCTTCCTGTCAACCAATTTATGCCTAC 
 
H1 shRNA 9     AGCCTCCTATTTTTTACGCGTAGATCTGGGAATCTAGATGCATTCGCGAG 
H1 Promoter    -------------------------------------------------- 
H1 shRNA 9 R1  -------------------------------------------------- 
   shRNA 9 R2  GCCTCCTATTTTTTACGCGTAGATCTGGG--------------------- 
 
 
Figure C.5: DNA sequence of H1 shRNA 9.  
The shRNA expression cassette is 100 % homologous to the designed primers. There was a single 
nucleotide insertion (G) and a G149A base change observed within the H1 promoter. The shRNA is 
comprised of the anti-guide sequence (blue), loop (green) and guide sequence with termination site 
(purple).   
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Figure C.6: Predicted structure of tRNA
Lys3 
shRNA expression cassettes.  
The tRNA
Lys3 
promoter starts transcription within the structure itself, thus the shRNAs will be 
transcribed attached to the acceptor arm of the tRNA
Lys3
.  The guide sequence (purple) is four 
nucleotides shorter than the guide sequences in U6 and H1 shRNA expression cassettes, to 
counteract for the increased length of the hairpin following transcription (i.e. transcribed tRNA
Lys3
 
promoter and hairpin. 
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tRNA
Lys3
 shRNA 5 CCCCTCGAGGTCGACGCCCGGATAGCTCAGTCGGTAGAGCATCAGACTTT 
tRNA
Lys3
 Promoter ---------------GCCCGGATAGCTCAGTCGGTTGAGCATCAGACTTT 
shRNA 5 Oligo   -------------------------------------------------- 
 
tRNA
Lys3
 shRNA 5  TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGTCGTGTGCGCTT 
tRNA
Lys3
 Promoter TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCG----------------
shRNA 5 Oligo   ----------------------------------GGCGTCGTGTGCGCTT 
 
tRNA
Lys3
 shRNA 5 TGCTTCGCCTTTGTGTAGGGTGAAGCGAAGTGCACACGGTTTTTTGCAGC 
tRNA
Lys3
 Promoter -------------------------------------------------- 
shRNA 5 Oligo   TGCTTCGCCTTTGTGTAGGGTGAAGCGAAGTGCACACGGTTTTTTGCA-- 
 
 
 
Figure C.7: Sequence analysis of tRNA
Lys3
 shRNA 5. 
A single base change T21A occurred in the tRNA
Lys3 
promoter (red). The shRNA sequence 
identified by the anti-guide (blue), loop (green) and guide sequence (purple) is 100% homologous to 
the hairpin predicted structure (Appendix C.6). The natural accepter arm is highlighted yellow. 
 
 
 
tRNA
Lys3
 shRNA 6  CCCCTCGAGGTCGACGCCCGGATAGCTCAGTCGGTAGAGCATCAGACTTT 
tRNA
Lys3
 Promoter ---------------GCCCGGATAGCTCAGTCGGTTGAGCATCAGACTTT 
shRNA 6 Oligo    -------------------------------------------------- 
 
tRNA
Lys3
 shRNA 6  TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGTACACCTCGCTT 
tRNA
Lys3
 Promoter TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCG---------------- 
shRNA 6 Oligo   ----------------------------------GGCGTACACCTCGCTT 
 
tRNA
Lys3
 shRNA 6  CACCTCTACTTTGTGTAGGCAGAGGTGAAGCGAAGTGCATTTTTTGCAGC 
tRNA
Lys3
 Promoter -------------------------------------------------- 
shRNA 6 Oligo   CACCTCTACTTTGTGTAGGCAGAGGTGAAGCGAAGTGCATTTTTTGCA-- 
 
 
 
Figure C.8: Sequence analysis of tRNA
Lys3
 shRNA 6. 
A single base change T21A occurred in the tRNA
Lys3 
promoter (red). The shRNA sequence 
identified by the anti-guide (blue), loop (green) and guide sequence (purple) is 100% homologous to 
the hairpin predicted structure (Appendix C.6). The natural accepter arm is highlighted yellow. 
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tRNA
Lys3
shRNA 8  CCCCTCGAGGTCGACGCCCGGATAGCTCAGTCGGTAGAGCATCAGACTTT 
tRNA
Lys3 
Promoter ---------------GCCCGGATAGCTCAGTCGGTTGAGCATCAGACTTT 
shRNA 8 Oligo   -------------------------------------------------- 
 
tRNA
Lys3
 shRNA 8 TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGCAACGTCAACAA 
tRNA
Lys3
 Promoter TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCG---------------- 
shRNA 8 Oligo   ----------------------------------GGCGCAACGTCAACAA 
 
tRNA
Lys3
 shRNA 8 CCAACCTTGTTTGTGTAGCAAGGTCGGTCGTTGACATTGTTTTTTGCAGC 
tRNA
Lys3 
Promoter -------------------------------------------------- 
shRNA 8 Oligo  CCAACCTTGTTTGTGTAGCAAGGTCGGTCGTTGACATTGTTTTTTGCA-- 
 
 
 
Figure C.9: Sequence analysis of tRNA
Lys3
 shRNA 8.  
A single base change T21A occurred in the tRNA
Lys3 
promoter (red). The shRNA sequence 
identified by the anti-guide (blue), loop (green) and guide sequence (purple) is 100% homologous to 
the hairpin predicted structure (Appendix C.6). The natural accepter arm is highlighted yellow. 
 
 
 
tRNA
Lys3
 shRNA 9 CCCCTCGAGGTCGACGCCCGGATAGCTCAGTCGGTAGAGCATCAGACTTT 
tRNA
Lys3
 Promoter ---------------GCCCGGATAGCTCAGTCGGTTGAGCATCAGACTTT 
shRNA 9 Oligo   -------------------------------------------------- 
 
tRNA
Lys3
 shRNA 9 TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGTAAGAAGCTGTA 
tRNA
Lys3
 Promoter TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCG---------------- 
shRNA 9 Oligo   ----------------------------------GGCGTAAGAAGCTGTA 
 
tRNA
Lys3
 shRNA 9 GGCACAAATATTGTGTAGATTTATGCCTACAGCCTCCTATTTTTTGCAGC 
tRNA
Lys3
 Promoter -------------------------------------------------- 
shRNA 9 Oligo   GGCACAAATATTGTGTAGATTTATGCCTACAGCCTCCTATTTTTTGCA-- 
 
 
 
Figure C.10: Sequence analysis of tRNA
Lys3
 shRNA 9.  
A single base change T21A occurred in the tRNA
Lys3 
promoter (red). The shRNA sequence 
identified by the anti-guide (blue), loop (green) and guide sequence (purple) is 100% homologous to 
the hairpin predicted structure (Appendix C.6). The natural accepter arm is highlighted yellow. 
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tRNA
Lys3
 shRNA 10 CCCCTCGAGGTCGACGCCCGGATAGCTCAGTCGGTAGAGCATCAGACTTT 
tRNA
Lys3
 Promoter ---------------GCCCGGATAGCTCAGTCGGTTGAGCATCAGACTTT 
shRNA 10 Oligo  -------------------------------------------------- 
 
tRNA
Lys3
 shRNA 10 TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGTTCGAGCCTCCG 
tRNA
Lys3
 Promoter TAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCG---------------- 
shRNA 10 Oligo  ----------------------------------GGCGTTCGAGCCTCCG 
 
tRNA
Lys3
 shRNA 10 AGTTGTGCTATTGTGTAGGGCACAGCTTGGAGGCTTGAATTTTTTGCAGC 
tRNA
Lys3
 Promoter -------------------------------------------------- 
shRNA 10 Oligo  AGTTGTGCTATTGTGTAGGGCACAGCTTGGAGGCTTGAATTTTTTGCA— 
 
 
 
Figure C.11: Sequence analysis of tRNA
Lys3
 shRNA 10.  
A single base change T21A occurred in the tRNA
Lys3 
promoter (red). The shRNA sequence 
identified by the anti-guide (blue), loop (green) and guide sequence (purple) is 100% homologous to 
the hairpin predicted structure (Appendix C.6). The natural accepter arm is highlighted yellow.
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Figure C.12: Analysis of RNA integrity extracted from Total, nuclear and cytoplasmic 
fractions.  
(A) Comparison of total and cytoplasmic RNA. Transfected Huh7 cells were fractionated by Method 
1. The cytoplasmic RNA is degraded. (B) Comparison of RNA extracted from whole, untransfected 
Huh7 cellsfrom fractions obtained using Method 1 and Method 2. Method 1 yielded relatively pure 
RNA (left). Alternative techniques for lysing the cells were tested using Method 1.  
 
Interpretation of Figure C.12: Lysing of the plasma membrane accompanied by vortexing yielded 
insufficient RNA, however it yielded more cytoplasmic RNA than lysis accompanied by 
resuspension. Lysis of cells using the dounce homogeniser yielded degraded RNA with insufficient 
cytoplasmic RNA. Vo – vortex; Re – resuspended by pipette. 
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Figure C.13: Analysis of integrity of RNA extracted using the PARIS™ Kit. 
(A) Total, nuclear and cytoplasmic RNA extrcted from non-transfected HepG.2.215 cells, yielded 
insufficient amounts of RNA from all three lysates  (B,C) RNA was extracted from transfected Huh7 
cells. The RNA yield was poor and insufficient, prompting an alternative method of RNA extraction 
to be implemented. 
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Figure C.14: RNA anaylysis of total, nuclear and cytoplasmic fractions.  
The RNA extracted from transfected Huh7 cells yielded sufficient amounts of pure, quality RNA for 
the majority of the fractions. Nuclear RNA was insuffcient for U6 shRNA 5, tRNA
Lys3
 Mock and 
tRNA
Lys3
 shRNA 5. 
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Figure C.15: Delivery efficiency of anti-HBV effecter sequences to the liver.  
psi-CHECK 2.2 was co-administered with the indicated plasmids to mice by hydrodynamic tail vein injection. Detection of the amount of Renilla 
luciferase sequence indicates the efficacy at which the DNA expressing plasmids were delivered to the liver.  
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Table C.1: P values for shRNA 5 and pri-miRNA-122/5 HBx Dual Luciferase Assay 
 
 
 
Table C.2: P values for shRNA 6 and pri-miRNA-122/6 HBx Dual Luciferase Assay 
Target:Effecter  U6 H1 tRNALys3 
Pri-miRNA-
122 
1:0.0025  0.0054 0.0753 0.2547 0.0406 
1:0.01  0.0027 0.0154 0.0576 0.0341 
1:0.05  0.0009 0.0022 0.0085 0.0757 
1:0.1  0.0007 0.0009 0.0009 0.0082 
1:10  0.0006 0.0006 0.0017 <0.0001 
 
 
 
 
 
 
 
Target:Effecter  U6 H1 tRNALys3 
Pri-miRNA-
122 
1:0.0025  0.0029 0.0455 0.0078 0.1792 
1:0.01  0.0004 0.0034 0.0065 0.2224 
1:0.05  0.0002 0.0005 0.0006 0.2008 
1:0.1  0.0001 0.0001 0.0003 0.0084 
1:10  <0.0001 <0.0001 0.0002 0.0022 
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Table C.3: P values for shRNA 8 and pri-miRNA-122/8 HBx Dual Luciferase Assay 
Target:Effecter  U6 H1 tRNALys3 
Pri-miRNA-
122 
1:0.0025  0.0528 0.2688 0.4706 0.0150 
1:0.01  0.0047 1.0000 0.0455 0.0354 
1:0.05  0.0022 0.0132 0.0494 0.0286 
1:0.1  0.0001 0.0008 0.1410 0.0066 
1:10  <0.0001 0.0001 0.0268 0.0060 
 
 
 
Table C.4: P values for shRNA 9 and pri-miRNA-122/9 HBx Dual Luciferase Assay 
Target:Effecter  U6 H1 tRNALys3 
Pri-miRNA-
122 
1:0.0025  0.0817 0.0178 0.7525 0.0751 
1:0.01  0.0005 0.0039 0.4734 0.0526 
1:0.05  0.0001 0.0003 0.0559 0.0539 
1:0.1  <0.0001 0.0001 0.0050 0.0131 
1:10  <0.0001 <0.0001 <0.0001 0.0001 
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Table C.5: P values for shRNA 10 and pri-miRNA-122/10 HBx Dual Luciferase Assay 
Target:Effecter  U6 H1 tRNALys3 
Pri-miRNA-
122 
1:0.0025  0.0029 0.0455 0.0078 0.1792 
1:0.01  0.0004 0.0034 0.0065 0.2224 
1:0.05  0.0002 0.0005 0.0006 0.2008 
1:0.1  0.0001 0.0001 0.0003 0.0084 
1:10  <0.0001 <0.0001 0.0002 0.0022 
 
 
 
Table C.6: Statistical analysis of in vitro HBsAg (P values) 
 
 
 
 
 
 
 
 
 
 
Effecter 
Sequence 
 U6 H1 tRNALys3 CMV 
5  0.0367 0.0198 0.0455 0.0058 
6  0.0120 0.0085 0.0205 0.0157 
8  0.0174 0.0617 0.1494 0.0688 
9  0.0091 0.0928 0.0184 0.0076 
10  0.0003 0.0188 0.4367 0.3050 
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Table C.7: Statistical analysis of in vitro Saturation Assay (P values) 
 
 
 
 
 
 
  
Effecter 
Sequence 
U6 H1 tRNALys3 CMV Mock 
5 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
6 <0.0001 <0.0001 <0.0001 0.0001 <0.0001 
